Inhibitors of KRas G12C and methods of using same
Compounds targeting the KRAS G12C variant provide a new approach to treating cancers with KRAS mutations by inhibiting KRAS G12C, addressing resistance to EGFR-targeted therapy and potentially reducing tumor growth and metastasis.
Patent Information
- Application Number
- JP2023171856
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-09-08
- Filing Date
- 2023-10-03
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2038-09-07
AI Technical Summary
There is a need for new medical treatments for cancers such as pancreatic cancer, lung adenocarcinoma, and colorectal cancer, particularly for patients with KRAS mutations, as existing therapies are ineffective due to KRAS mutations conferring resistance to EGFR-targeted therapy.
Development of compounds, such as those represented by Formulas I and II, which act as inhibitors of the KRAS G12C variant, capable of inactivating the KRAS G12C variant and potentially treating various disease states, including tumor conditions.
The compounds effectively inhibit KRAS G12C, offering potential therapeutic benefits for cancers with KRAS mutations by potentially reducing tumor growth and metastasis, and can be administered in various forms to achieve desired treatment outcomes.
Smart Images

Figure 0007595724000001 
Figure 0007595724000002 
Figure 0007595724000003
Abstract
Description
[Technical field]
[0001] This application is filed with a sequence listing in electronic format. The sequence listing is provided as a file named A-2202-US-NP_SeqList_090618_ST25.txt, created on September 7, 2018, and is 15.13 kb in size. The information in the electronic sequence listing is incorporated herein by reference in its entirety.
[0002] The present invention relates to compounds that can act as inhibitors of KRAS G12C mutants and compositions that contain compounds that are inhibitors of KRAS G12C mutants.The compounds and compositions can be used to inactivate KRAS G12C mutants and treat various disease conditions.One example of the field in which such compounds can be used is in the treatment of tumor conditions. [Background technology]
[0003] KRAS gene mutations are common in pancreatic cancer, lung adenocarcinoma, colon cancer, gallbladder cancer, thyroid cancer and bile duct cancer. KRAS mutations are also observed in about 25% of NSCLC patients, and several studies have shown that KRAS mutations are a negative prognostic factor for NSCLC patients. Recently, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations have been found to confer resistance to epidermal growth factor receptor (EGFR)-targeted therapy in colon cancer, and thus, the mutation status of KRAS can provide important information before prescribing TKI therapy. Taken together, there is a need for new medical treatments for patients with pancreatic cancer, lung adenocarcinoma or colon cancer, including patients diagnosed with such cancers characterized by KRAS mutations and those who have progressed after chemotherapy. Summary of the Invention [Means for solving the problem]
[0004] In one aspect of the invention, an embodiment is a compound of formula (I) [ka] (In the formula, A is independently N or CH; W is independently N or CH; One or both of A and W is N; R 1 and R 2 are independently branched or linear C 1~6 is alkyl; R 3 is one or two R 5 is a phenyl substituted by a substituent; R 5 is independently selected from one or more of halo, -OH, or NH; R 4 is a halo) or a stereoisomer thereof, a pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the stereoisomer thereof. In another aspect of the invention, another embodiment of the invention includes a compound having the structure of formula (Ia): [ka] or a pharma- ceutically acceptable salt thereof.
[0005] The compound of embodiment 1 or 2, wherein A is N.
[0006] The compound of embodiment 1 or 2, wherein A is CH.
[0007] The compound of embodiment 1 or 2, wherein W is N.
[0008] The compound of embodiment 1 or 2, wherein W is CH.
[0009] R 1 The compound of any one of embodiments 1-6, wherein is CH3.
[0010] R 1 The compound of any one of embodiments 1-6, wherein is CH(CH3)2.
[0011] R 2 The compound of any one of embodiments 1-8, wherein is CH3.
[0012] R 2 The compound of any one of embodiments 1-8, wherein is CH(CH3)2.
[0013] R 5 The compound of any one of embodiments 1-10, wherein is halo.
[0014] R 5 The compound of embodiment 11, wherein
[0015] R 5 The compound of any one of embodiments 1-10, wherein is —OH.
[0016] R 5 The compound of any one of embodiments 1-10, wherein is -NH2.
[0017] R 3 teeth, [ka] The compound of any one of embodiments 1-10, wherein
[0018] R 3 teeth, [ka] 16. The compound of embodiment 15, wherein
[0019] R 3 teeth, [ka] 16. The compound of embodiment 15, wherein
[0020] R 3 teeth, [ka] 16. The compound of embodiment 15, wherein
[0021] R 4 The compound of any one of embodiments 1-18, wherein is halo.
[0022] R 4 The compound of embodiment 19, wherein is Cl.
[0023] R 4 The compound of embodiment 19, wherein
[0024] In another aspect of the invention, another embodiment of the invention is a compound of formula (II) [ka] (In the formula, A is independently N or CH; W is independently N or CH; One or both of A and W is N; R 1 and R 2 are independently branched or linear C 1~6 is alkyl; R 3 is one or two R 5 is a phenyl substituted by a substituent; R 5 is independently selected from one or more of halo, -OH, or NH; and R 4 is a halo) or a stereoisomer thereof, a pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the stereoisomer.
[0025] Formula (IIa) [ka] 23. The compound of embodiment 22 having the structure: or a pharma- ceutically acceptable salt thereof.
[0026] The compound of embodiment 22 or 23, wherein A is N.
[0027] The compound of embodiment 22 or 23, wherein A is CH.
[0028] The compound of embodiment 22 or 23, wherein W is N.
[0029] 24. The compound of embodiment 22 or 23, wherein W is CH.
[0030] R 1 The compound of any one of embodiments 22-27, wherein is CH3.
[0031] R 1 The compound of any one of embodiments 22-27, wherein is CH(CH3)2.
[0032] R 2 The compound of any one of embodiments 22-29, wherein is CH3.
[0033] R 2 The compound of any one of embodiments 22-29, wherein is CH(CH3)2.
[0034] R 5 The compound of any one of embodiments 22-31, wherein is halo.
[0035] R 5 The compound of embodiment 32, wherein is F.
[0036] R 5 The compound of any one of embodiments 22-31, wherein is —OH.
[0037] R 5 The compound of any one of embodiments 22-31, wherein is -NH2.
[0038] R 3 teeth, [ka] The compound of any one of embodiments 22-31, wherein
[0039] R 3 teeth, [ka] The compound of embodiment 36, wherein
[0040] R 3 teeth, [ka] The compound of embodiment 36, wherein
[0041] R 3 teeth, [ka] The compound of embodiment 36, wherein
[0042] R 4 The compound of any one of embodiments 22-39, wherein is halo.
[0043] R 4 The compound of embodiment 40, wherein is Cl.
[0044] R 4 The compound of embodiment 40, wherein is F.
[0045] In another aspect of the invention, another embodiment of the invention comprises: [ka] [ka] [ka] [ka] or a stereoisomer thereof, a pharma- ceutically acceptable salt thereof, or a pharma- ceutically acceptable salt of the stereoisomer.
[0046] In another aspect of the invention, another embodiment of the invention comprises: [ka] [ka] [ka] The present invention includes compounds having a structure selected from:
[0047] The compound of embodiment 44, in the form of a pharma- ceutically acceptable salt.
[0048] In another aspect of the invention, another embodiment of the invention includes a pharmaceutical composition comprising a compound of any one of embodiments 1-45 and a pharma- ceutically acceptable excipient.
[0049] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0050] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0051] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0052] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0053] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0054] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0055] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0056] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0057] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0058] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0059] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0060] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0061] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0062] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0063] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0064] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0065] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0066] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0067] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0068] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0069] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0070] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0071] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0072] In another aspect of the invention, another embodiment of the invention is a structure [ka] The compounds include those having the formula:
[0073] In another aspect of the invention, another embodiment of the invention includes a compound of any one of Examples 47-70 in the form of a pharma- ceutically acceptable salt.
[0074] In another aspect of the invention, another embodiment of the invention includes a pharmaceutical composition comprising a compound of any one of embodiments 1-45 and 47-71 and a pharma- ceutically acceptable excipient.
[0075] In another aspect of the invention, another embodiment of the invention includes a method of inhibiting KRAS G12C in a cell, comprising contacting a cell with a compound of any one of embodiments 1-45 and 47-71 or a composition of embodiment 46 or 72.
[0076] In another aspect of the invention, another embodiment of the invention includes a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound of any one of embodiments 1-45 and 47-71, or a composition of embodiment 46 or 72.
[0077] The method of embodiment 74, wherein the cancer is lung cancer, pancreatic cancer or colon cancer.
[0078] Numerous other embodiments of the compounds of Formulas I, Ia, II, and IIa are described herein.
[0079] Also provided is a pharmaceutical composition comprising at least one pharma- ceutically acceptable excipient, carrier, or diluent and a compound according to any one of the embodiments or a pharma- ceutically acceptable salt thereof, a tautomer thereof, a pharma- ceutically acceptable salt of a tautomer, a stereoisomer of any of the foregoing, or a mixture thereof.
[0080] The compounds disclosed herein may be in the form of pharma- ceutically acceptable salts.The compounds provided herein may be formulated into pharmaceutical preparations comprising the compounds disclosed herein and pharma- ceutically acceptable excipients.
[0081] Also provided is a method of inhibiting KRAS G12C in a cell, comprising contacting the cell with a compound or composition disclosed herein.Further provided is a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound or composition disclosed herein.In some embodiments, the cancer is lung cancer, pancreatic cancer or colon cancer.
[0082] Other objects, features and advantages of the present invention will become apparent to those skilled in the art from the following description and claims. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0083] definition
[0084] [Table 1]
[0085] [Table 2]
[0086] [Table 3]
[0087] In connection with the description of the present invention (particularly in connection with the claims), the use of the terms "a", "an", "the" and similar referents should be construed to encompass both the singular and the plural unless otherwise indicated. The recitation of ranges of values herein is merely intended to serve as a shorthand method of individually referring to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated herein as if it were individually recited herein. The use of any examples or exemplary language provided herein (e.g., "such as") is intended to better illustrate the invention and is not a limitation on the scope of the invention unless otherwise asserted. No language in this specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0088] As used herein, the term "alkyl" refers to straight chain and branched C1-C8 hydrocarbon groups, including, but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, t-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl. The term Cm-n means that the alkyl group has from "m" to "n" carbon atoms. The term "alkylene" refers to an alkyl group having a substituent. An alkyl (e.g., methyl) or alkylene (e.g., -CH2-) group may be substituted with one or more, typically one to three, independently selected from, for example, halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, nitro, cyano, alkylamino, -C1-8 alkyl, -C2-8 alkenyl, -C2-8 alkynyl, -NC, amino, -CO2H, -CO2C1-C8 alkyl, -OCOC1-C8 alkyl, -C3-C10 cycloalkyl, -C3-C10 heterocycloalkyl, -C5-C10 aryl, and -C5-C10 heteroaryl. The term "haloalkyl" specifically refers to an alkyl group in which at least one, for example one to six or all, of the alkyl group's hydrogens are replaced with a halo atom.
[0089] The terms "alkenyl" and "alkynyl" refer to alkyl groups that further contain double or triple bonds, respectively.
[0090] As used herein, the term "halo" refers to fluoro, chloro, bromo, and iodo. The term "alkoxy" is defined as -OR, where R is alkyl.
[0091] As used herein, the terms "amino" or "amine" refer interchangeably to the group -NR2, where each R is, for example, H or a substituent. In some embodiments, the amino group is further substituted to form an ammonium ion, for example, NR3+. The ammonium moiety is specifically included in the definition of "amino" or "amine". The substituent can be, for example, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, amido, or carboxylate. The R group can be further substituted with one or more, for example, 1 to 4 groups selected from, for example, halo, cyano, alkenyl, alkynyl, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, urea, carbonyl, carboxylate, amine, and amide. An "amide" or "amido" group refers interchangeably to a group similar to an amine or amino group, but further including -C(O), for example, -C(O)NR2. Some possible amino or amido groups (some with an optional alkylene group, such as alkylene-amino or alkylene-amido) include -CH2NH2, -CH(CH3)NH2, -CH(CH3)2NH2, -CH2CH2NH2, -CH2CH2N(CH3)2, -CH2NHCH3, -C(O)NHCH3, -C(O)N(CH3)2, -CH2C(O)NHphenyl, -CH2NHC(O)CH3, -CH2NHCH2CH2OH, -CH2NHCH2CO2H and -CH2NH(CH3)CH2CO2CH3.
[0092] Collectively, antibodies form a family of plasma proteins known as immunoglobulins and are composed of immunoglobulin domains. (Janeway et al., Immunobiology: The Immune System in Health and Disease, 4 thed., Elsevier Science Ltd. / Garland Publishing, 1999. As used herein, the term "antibody" refers to a protein having a conventional immunoglobulin type, including heavy and light chains, and including a variable region and a constant region. For example, an antibody may be an IgG, which is a pair of two identical polypeptide chains in a "Y-shaped" structure, each pair having one "light chain" (typically having a molecular weight of about 25 kDa) and one "heavy chain" (typically having a molecular weight of about 50-70 kDa). An antibody has a variable region and a constant region. In the IgG type, the variable region is generally about 100-110 or more amino acids, includes three complementarity determining regions (CDRs), and is primarily responsible for antigen recognition and is substantially different from other antibodies that bind to different antigens. The constant region enables the antibody to recruit cells and molecules of the immune system. The variable region consists of the N-terminal regions of the light and heavy chains, respectively, while the constant region consists of the C-terminal portions of the heavy and light chains, respectively. (Janeway et al., “Structure of the Antibody Molecule and the Immunoglobulin Genes”, Immunobiology: The Immune System in Health and Disease, 4 th ed.Elsevier Science Ltd. / Garland Publishing, (1999)).
[0093] The general structure and characteristics of antibody CDRs have been described in the art. Briefly, in an antibody scaffold, CDRs are embedded within the frameworks of heavy and light chain variable regions and constitute, for the most part, the regions involved in antigen binding and recognition. A variable region usually comprises at least three heavy or light chain CDRs within a framework region (designated framework regions 1-4, FR1, FR2, FR and FR4 by Kabat et al., 1991; see also Chothia and Lesk, 1987, supra) (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Public Health Service NIH, Bethesda, Md.; Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917; see also Chothia et al., 1989, Nature 342:877-883).
[0094] The antibody may comprise any constant region known in the art. Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, defining the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has multiple subclasses, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has subclasses, including, but not limited to, IgM1 and IgM2. The embodiments of the present disclosure include all such classes or isotypes of antibodies. The light chain constant region may be, for example, a kappa- or lambda-type light chain constant region, such as a human kappa- or lambda-type light chain constant region. The heavy chain constant region may be, for example, an alpha-, delta-, epsilon-, gamma-, or mu-type heavy chain constant region, such as a human alpha-, delta-, epsilon-, gamma-, or mu-type heavy chain constant region. Thus, in exemplary embodiments, the antibody is of the isotype IgA, IgD, IgE, IgG or IgM, including any one of IgG1, IgG2, IgG3 or IgG4.
[0095] The antibody may be a monoclonal or polyclonal antibody. In some embodiments, the antibody comprises a sequence substantially similar to a naturally occurring antibody produced by a mammal, such as a mouse, rabbit, goat, horse, chicken, hamster, human, etc. In this regard, the antibody may be considered a mammalian antibody, such as a mouse antibody, a rabbit antibody, a goat antibody, a horse antibody, a chicken antibody, a hamster antibody, a human antibody, etc. In certain aspects, the antibody is a human antibody. In certain aspects, the antibody is a chimeric antibody or a humanized antibody. The term "chimeric antibody" refers to an antibody that contains domains from two or more different antibodies. A chimeric antibody can, for example, contain a constant domain from one species and a variable domain from a second species, or more commonly, contain a contiguous amino acid sequence from at least two species. A chimeric antibody can also contain domains from two or more different antibodies within the same species. The term "humanized" when used in reference to an antibody refers to an antibody that has at least a CDR region derived from a non-human source that has been engineered to have a structure and immune function more similar to a true human antibody than the original source antibody. For example, humanization can involve transplanting CDRs from a non-human antibody, such as a mouse antibody, into a human antibody. Humanization can also involve selecting amino acid substitutions to make the non-human sequence more similar to the human sequence.
[0096] Antibodies can be cleaved into fragments by enzymes such as, for example, papain and pepsin. Papain cleaves antibodies to produce two Fab fragments and an Fc fragment. Pepsin cleaves antibodies to produce an F(ab')2 fragment and a pFc' fragment. As used herein, the term "antigen-binding antibody fragment" refers to a portion of an antibody molecule that can bind to the antigen of the antibody and is also known as an "antigen-binding fragment" or "antigen-binding portion." In exemplary cases, the antigen-binding antibody fragment is a Fab fragment or an F(ab')2 fragment.
[0097] The structure of antibodies has been exploited to create a wide range of alternative forms, ranging in molecular weight from at least about 12 to 150 kDa, and ranging in valency (n) from monomers (n=1) to dimers (n=2), trimers (n=3), tetramers (n=4), and potentially even higher, referred to herein as "antibody protein products." Antibody protein products include those based on the complete antibody structure and those that mimic antibody fragments that retain full antigen-binding ability, such as scFv, Fab, and VHH / VH (discussed below). The smallest antigen-binding antibody fragment that retains a complete antigen-binding site is the Fv fragment, consisting entirely of the variable (V) region. The V regions are linked to scFv (single chain variable fragment) using soluble and flexible amino acid peptide linkers to stabilize the molecule, or constant (C) domains are added to the V regions to generate Fab fragments [antigen-binding fragments]. Both scFv and Fab fragments can be easily produced in host cells, e.g. prokaryotic host cells. Other antibody protein products include disulfide bond stabilized scFv (ds-scFv), single chain Fab (scFab) and minibodies (miniAbs) including dimeric and multimeric antibody forms such as diabodies, triabodies and tetrabodies or different forms consisting of scFv linked to oligomerization domains. The smallest fragments are the VHH / VH of camelized heavy chain Abs and single domain Abs (sdAbs). The building blocks most frequently used to create new antibody formats are single chain variable (V) domain antibody fragments (scFv), which contain V domains (VH and VL domains) derived from heavy and light chains linked by a peptide linker of about 15 amino acid residues. Peptibodies or peptide Fc fusions are yet another antibody protein product. The structure of a peptibody consists of a biologically active peptide grafted into the Fc domain. Peptibodies are well described in the art, see, e.g., Shimamoto et al., mAbs 4(5):586-591 (2012).
[0098] Other antibody protein products include single chain antibodies (SCAs); diabodies; triabodies; tetrabodies; bispecific or trispecific antibodies, etc. Bispecific antibodies can be divided into five major classes: BsIgG, adduct IgG, BsAb fragments, bispecific fusion proteins, and BsAb conjugates. See, for example, Spiess et al., Molecular Immunology 67(2)Part A:97-106(2015).
[0099] As used herein, the term "aryl" refers to 6~14 monocyclic or polycyclic aromatic groups of the formula C 6~10 or a monocyclic or bicyclic aromatic group of C 10~14 It refers to a polycyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl. Aryl refers to a C cyclic aromatic ring in which one ring is aromatic and the other ring is saturated, partially unsaturated, or aromatic, such as dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). 10~14 Unless otherwise indicated, aryl groups may be unsubstituted or substituted with, for example, halo, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C2-8 alkynyl, -CF3, -OCF3, -NO2, -CN, -NC, -OH, alkoxy, amino, -CO2H, -CO2C1-C8 alkyl, -OCOC1-C8 alkyl, -C3-C 10 Cycloalkyl, -C3~C 10 Heterocycloalkyl, -C5~C 10 Aryl and -C5~C 10 It may be substituted with one or more, particularly 1 to 4, groups independently selected from heteroaryl.
[0100] As used herein, the term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic carbocyclic ring, which may be fused, bridged, or spiro. The carbocyclic ring may have 3 to 10 carbon ring atoms. Possible carbocyclic rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and cyclononyl.
[0101] As used herein, the term "heterocycloalkyl" refers to a monocyclic or polycyclic (e.g., bicyclic), saturated or partially unsaturated ring system containing a total of three or more (e.g., 3-12, 4-10, 4-8, or 5-7) atoms, of which one to five (e.g., one, two, three, four, or five) atoms are independently selected from nitrogen, oxygen, and sulfur. Non-limiting examples of heterocycloalkyl groups include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, dihydropyrrolyl, morpholinyl, thiomorpholinyl, dihydropyridinyl, oxacycloheptyl, dioxacycloheptyl, thiacycloheptyl, and diazacycloheptyl.
[0102] Unless otherwise specified, a cycloalkyl or heterocycloalkyl group may be unsubstituted or substituted with one or more, particularly one to four, groups. Some possible substituents include halo, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, -OCF3, -NO2, -CN, -NC, -OH, alkoxy, amino, -CO2H, -CO2C1-C8 alkyl, -OCOC1-C8 alkyl, -C3-C 10 Cycloalkyl, -C3~C 10 Heterocycloar, -C5~C 10 Aryl and -C5~C 10 Examples of such radicals include heteroaryl.
[0103] As used herein, the term "heteroaryl" refers to a monocyclic or polycyclic ring system (e.g., bicyclic) containing 1-3 aromatic rings and containing 1-4 (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur in the aromatic rings. In certain embodiments, a heteroaryl group has 5-20, 5-15, 5-10, or 5-7 atoms. Heteroaryl also refers to C10-14 bicyclic and tricyclic rings in which one ring is aromatic and the other ring is saturated, partially unsaturated, or aromatic. Examples of heteroaryl groups include furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, triazolyl, benzofuranyl, benzimidazolyl, benzisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzothiophenyl, and benzotriazolyl. Examples of heteroaryl include, but are not limited to, aryl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quiazolinyl, thiadiazolopyrimidyl and thienopyridyl. Unless otherwise indicated, heteroaryl groups may be unsubstituted or substituted with one or more, particularly 1 to 4 or 1 or 2, substituents. Possible substituents include halo, -C1-8 alkyl, -C2-8 alkenyl, -C2-8 alkynyl, -OCF3, -NO2, -CN, -NC, -OH, alkoxy, amino, -CO2H, -CO2C1-C8 alkyl, -OCOC1-C8 alkyl, -C3-C 10 Cycloalkyl, -C3~C 10 Heterocycloar, -C5~C 10 Aryl and -C5~C 10 Examples of such radicals include heteroaryl.
[0104] As used herein, the term Boc refers to the structure [ka] Refers to...
[0105] As used herein, the term Cbz refers to the structure [ka] Refers to...
[0106] Compounds of the Disclosure Provided herein are KRAS inhibitors having the structure of one of Formulas I, Ia, II and IIa, discussed in more detail below.
[0107] The compounds disclosed herein include all pharma- ceutically acceptable isotopically labeled compounds in which one or more atoms of the compounds disclosed herein are replaced by an atom having the same atomic number, but an atomic mass or mass number different from that usually found in nature. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 31P, 32P, 35S, 18F, 36Cl, 123I, and 125I, respectively. These radiolabeled compounds may be useful, for example, to facilitate the determination or measurement of the efficacy of a compound by characterizing the binding affinity to a site or mode of action or a pharmacologically important site of action. Certain isotopically labeled compounds of the present disclosure, such as those incorporating a radioisotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotopes tritium, ie 3H, and carbon-14, ie 14C, are particularly useful for this purpose in view of their ease of incorporation and rapid means of detection.
[0108] Substitution with heavier isotopes such as deuterium, ie, 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in some circumstances.
[0109] Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of structure (I) can generally be prepared by conventional techniques known to those of skill in the art, or by methods analogous to those described in the Preparations and Examples below, substituting the appropriate isotopically labeled reagents for previously used non-labeled reagents.
[0110] Isotopically labeled compounds disclosed herein can generally be prepared by conventional techniques known to those of skill in the art, or by methods analogous to those described in the accompanying Examples and Schemes, substituting an appropriate isotopically labeled reagent for a previously used non-labeled reagent.
[0111] Certain compounds as disclosed herein may exist as stereoisomers (i.e., isomers that differ only in the spatial arrangement of atoms), including optical isomers and conformers (or conformers). The compounds disclosed herein include both pure individual stereoisomer preparations and enriched preparations of each, as well as both racemic mixtures of such stereoisomers, as well as all stereoisomers of individual diastereomers and enantiomers that can be separated according to methods known to those skilled in the art. Additionally, the compounds disclosed herein include all tautomeric forms of those compounds.
[0112] Certain compounds disclosed herein may exist as atropisomers, which are conformational stereoisomers that arise when rotation around a single bond in a molecule is hindered or very slowed down as a result of steric interactions with other parts of the molecule. The compounds disclosed herein include all atropisomers, both as pure individual atropisomer preparations, concentrated preparations of each, or non-specific mixtures of each. If the rotation barrier around a single bond is sufficiently high and the interconversion between conformations is sufficiently slow, separation and isolation of isomeric species may be possible. Separation and isolation of isomeric species is appropriately indicated by the well-known and commonly accepted symbols "M" or "P".
[0113] In another embodiment, these compounds may be used as intermediates in the process of making the compounds of the present application.
[0114] In another embodiment, these compounds may be in the form of a pharma- ceutically acceptable salt, as well as in a pharmaceutical formulation containing pharma- ceutically acceptable excipients.
[0115] Specific contemplated compounds include those listed in Table 1.
[0116] [Table 4]
[0117] [Table 5]
[0118] [Table 6]
[0119] [Table 7]
[0120] Synthesis of the Disclosed Compounds The compounds disclosed herein can be synthesized via several specific methods. The examples outlining specific synthetic routes and the general schemes below are intended to provide guidance to a synthetic chemist of ordinary skill who will readily appreciate that solvents, concentrations, reagents, protecting groups, order of synthetic steps, times, temperatures, and the like, can be varied as necessary and well within the skill and judgment of the artisan.
[0121] Suitable protecting groups and deprotecting reagents are known to those skilled in the art, for example, as discussed in Greene's Protective Groups in Organic Synthesis.
[0122] Contemplated halogenating agents include, but are not limited to, chlorine, bromine, N-chlorosuccinimide, and N-bromosuccinimide, optionally in the presence of a catalyst (e.g., iron or aluminum). A synthetic chemist of ordinary skill will readily appreciate that other halogenating agents and catalysts can be used.
[0123] Possible amidating agents include, but are not limited to, N,N'-diisopropylcarbodiimide, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, thionyl chloride, isobutyl chloroformate, diethyl cyanophosphonate, carbonyldiimidazole and polyphosphonic anhydride. A synthetic chemist of ordinary skill will readily understand that other amidating agents can be used.
[0124] Contemplated sulfurizing agents include, but are not limited to, sulfur, phosphorus pentasulfide, and Lawesson's reagent. A synthetic chemist of ordinary skill will readily appreciate that other sulfurizing agents can be used.
[0125] Possible oxidizing agents include, but are not limited to, hydrogen peroxide, iodobenzene diacetate, t-butyl hydroperoxide, N-bromosuccinimide, and ammonium peroxodisulfate. A synthetic chemist of ordinary skill will readily appreciate that other oxidizing agents can be used.
[0126] Possible activating agents include, but are not limited to, sodium nitrite and t-butyl nitrite. A synthetic chemist of ordinary skill will readily appreciate that other activating agents can be used.
[0127] Possible cross-coupling reactions include, but are not limited to, Suzuki coupling, Negishi coupling, Hiyama coupling, Kumada coupling and Stille coupling.
[0128] Pharmaceutical Compositions, Administration and Routes of Administration Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, together with a pharma- ceutically acceptable excipient, such as a diluent or carrier. Compounds and pharmaceutical compositions suitable for use in the present invention include those in which the compound can be administered in an amount effective to achieve its intended purpose. Administration of the compounds is described in more detail below.
[0129] Suitable pharmaceutical formulations can be determined by those skilled in the art according to the route of administration and the desired dosage. For example, see Remington's Pharmaceutical Sciences, 1435-712 (18th ed., Mack Publishing Co, Easton, Pennsylvania, 1990). Formulations can affect the physical state, stability, in vivo release rate and in vivo excretion rate of the administered drug. Depending on the route of administration, suitable doses can be calculated according to body weight, body surface area or organ size. Further refinement of calculations required to determine appropriate therapeutic doses can be routinely performed by those skilled in the art without undue experimentation, especially in light of the dosage information and assays disclosed herein and pharmacokinetic data obtained in animal or human clinical trials.
[0130] The phrases "pharmacologically acceptable" or "pharmacologically acceptable" refer to molecular entities and compositions that do not produce adverse allergic or other untoward reactions when administered to animals or humans. As used herein, "pharmacologically acceptable excipients" include any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such excipients for pharma- ceutical active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the therapeutic composition, its use in the therapeutic composition is contemplated. Supplementary active ingredients can also be incorporated into the composition. In an exemplary embodiment, the formulation comprises corn syrup solids, high oleic safflower oil, coconut oil, soybean oil, L-leucine, tricalcium phosphate, L-tyrosine, L-proline, L-lysine acetate, DATEM (emulsifier), L-glutamine, L-valine, dipotassium phosphate, L-isoleucine, L-arginine, L-alanine, glycine, L-asparagine monohydrate, L-serine, potassium citrate, L-threonine, sodium citrate, magnesium chloride, L-histidine, L-methionine, ascorbic acid, calcium carbonate, L-glutamic acid, L-cystine dihydrochloride. , L-tryptophan, L-aspartic acid, choline chloride, taurine, m-inositol, ferrous sulfate, ascorbyl palmitate, zinc sulfate, L-carnitine, alpha-tocopheryl acetate, sodium chloride, niacinamide, mixed tocopherols, calcium pantothenate, copper sulfate, thiamine chloride hydrochloride, vitamin A palmitate, manganese sulfate, riboflavin, pyridoxine hydrochloride, folic acid, beta-carotene, potassium iodide, phylloquinone, biotin, sodium selenate, chromium chloride, sodium molybdate, vitamin D3, and cyanocobalamin.
[0131] The compounds may be present in the pharmaceutical composition as pharma- ceutically acceptable salts. As used herein, "pharmaceutically acceptable salts" includes, for example, base addition salts and acid addition salts.
[0132] Pharmaceutically acceptable base addition salts can be formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Pharmaceutically acceptable salts of compounds can also be prepared with pharma-ceutically acceptable cations. Suitable pharma-ceutically acceptable cations are well known to those skilled in the art and include alkali, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or bicarbonates are also possible. Examples of metals used as cations include sodium, potassium, magnesium, ammonium, calcium or iron. Examples of suitable amines include isopropylamine, trimethylamine, histidine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine and procaine.
[0133] Pharmaceutically acceptable acid addition salts include salts of inorganic or organic acids. Examples of suitable acid salts include hydrochloride, formate, acetate, citrate, salicylate, nitrate, and phosphate. Other suitable pharma- ceutically acceptable salts are well known to those skilled in the art, such as formic acid, acetic acid, citric acid, oxalic acid, tartaric acid, or mandelic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or phosphoric acid; organic carboxylic acids, sulfonic acids, sulfoacids, or phosphoacids or N-substituted sulfamic acids, such as acetic acid, trifluoroacetic acid (TFA), propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, ethylenediaminetetraacetate ... and with the 20 alpha amino acids involved in the synthesis of natural proteins, such as glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane 1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene 2-sulfonic acid, naphthalene 1,5-disulfonic acid, 2- or 3-phosphoglyceric acid, glucose 6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamate) or with other acid organic compounds, such as ascorbic acid.
[0134] Pharmaceutical compositions containing the compounds disclosed herein can be manufactured in a conventional manner, for example by conventional mixing, dissolving, granulating, dragee-making, pulverizing, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation depends on the route of administration chosen.
[0135] For oral administration, suitable compositions can be easily formulated by combining the compounds disclosed herein with pharma- ceutically acceptable excipients, such as carriers well known in the art. Such excipients and carriers allow the compounds of the present invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by the patient to be treated. Pharmaceutical preparations for oral use can be obtained by adding the compounds disclosed herein with solid excipients, optionally grinding the resulting mixture, and processing the granulated mixture, after adding suitable auxiliaries as necessary, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers and cellulose preparations. Disintegrants can be added as necessary. Pharmaceutically acceptable ingredients are well known for various types of formulations, and can be, for example, binders (e.g., natural or synthetic polymers), lubricants, surfactants, sweeteners and flavorings, coating materials, preservatives, dyes, thickeners, adjuvants, antibacterial agents, antioxidants, and carriers for various formulation types.
[0136] When a therapeutically effective amount of a compound disclosed herein is administered orally, the composition is typically in the form of a solid (e.g., a tablet, capsule, pill, powder or lozenge) or a liquid preparation (e.g., an aqueous suspension, solution, elixir or syrup).
[0137] When administered in tablet form, the composition may further contain a functional solid, such as gelatin or an adjuvant, and / or a functional solid carrier. The tablet, capsule, and powder may contain about 1 to about 95% of the compound, preferably about 15 to about 90% of the compound.
[0138] When administered in liquid or suspension form, functional liquids and / or functional liquid carriers such as water, petroleum, or oils of animal or plant origin can be added. The liquid form of the composition can further include saline solution, sugar alcohol solution, dextrose or other sugar solution, or glycol. When administered in liquid or suspension form, the composition can contain about 0.5 to about 90% by weight of the compound disclosed herein, preferably about 1 to about 50% of the compound disclosed herein. In one contemplated embodiment, the liquid carrier is non-aqueous or substantially non-aqueous. For administration in liquid form, the composition can be provided as a rapidly dissolving solid formulation that is dissolved or suspended immediately prior to administration.
[0139] When a therapeutically effective amount of the compound disclosed herein is administered by intravenous, cutaneous or subcutaneous injection, the composition is in the form of a pyrogen-free parenterally acceptable aqueous solution. Preparation of such parenterally acceptable solutions, with due consideration of pH, isotonicity, stability, and the like, is within the skill of the art. A preferred composition for intravenous, cutaneous or subcutaneous injection typically contains an isotonic vehicle in addition to the compound disclosed herein. Such compositions can be prepared for administration as a solution of a free base or a pharmacologically acceptable salt in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof, as well as in oils. Under ordinary conditions of storage and use, these preparations can optionally contain a preservative to prevent the growth of microorganisms.
[0140] Injectable compositions can include sterile aqueous solutions, suspensions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions, suspensions or dispersions. In all embodiments, the form must be sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be protected against the contaminating action of microorganisms such as bacteria and fungi, optionally by including preservatives. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. In one possible embodiment, the carrier is non-aqueous or substantially non-aqueous. The proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, the maintenance of the required particle size in the case of dispersion embodiments, and the use of surfactants. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many embodiments, it is preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0141] Sterile injection solution is prepared by incorporating the active compound in the required amount in a suitable solvent together with various other necessary ingredients listed above, followed by sterilization by filtration.Generally, dispersion is prepared by incorporating various sterilized active ingredients into a sterile vehicle that contains a basic dispersion medium and other desired ingredients from the ingredients listed above.In the embodiment of sterile powder for preparing sterile injection solution, the preferred preparation method is vacuum drying and freeze-drying technique, which produces powder of active ingredient and any additional desired ingredients from its solution that has been previously sterile-filtered.
[0142] Slow or sustained release formulations can also be prepared to provide a controlled release of the active compound in contact with the fluids in the digestive tract and to provide a substantially constant and effective level of the active compound in plasma. For example, the release can be controlled by one or more of dissolution, diffusion and ion exchange. Furthermore, the slow release approach can enhance absorption via saturable or restricted pathways in the digestive tract. For example, the compound can be embedded for this purpose in a polymer matrix of a biodegradable polymer, a water-soluble polymer or a mixture of both, and optionally a suitable surfactant. Embedding in this context can mean incorporating microparticles in a polymer matrix. Controlled release formulations can also be obtained by encapsulation of dispersed microparticles or emulsified microdroplets via known dispersion or emulsion coating techniques.
[0143] For administration by inhalation, the compounds of the present invention are conveniently delivered in the form of an aerosol spray dispensed from a pressurized pack or nebulizer using a suitable propellant.In pressurized aerosol embodiments, the dosage unit can be determined by providing a valve to deliver a metered amount.Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator can be formulated to contain a powder mix of the compound and a suitable powder base, such as lactose or starch.
[0144] The compounds disclosed herein can be formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion).The preparation for injection can be provided in unit dosage form (e.g., in ampoules or multi-dose containers) with added preservatives.The composition can take the form of a suspension, solution or emulsion in an oily or aqueous vehicle, and can contain formulating agents such as suspending agents, stabilizing agents and / or dispersing agents.
[0145] Pharmaceutical preparations for parenteral administration include aqueous solutions of the compound in water-soluble form. Additionally, suspensions of the compound can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compound and allow for the preparation of highly concentrated solutions. Alternatively, the compositions of the present invention can be in powder form for constitution with a suitable vehicle (e.g., sterile pyrogen-free water) before use.
[0146] The compounds disclosed herein can also be formulated into rectal compositions such as suppositories or retention enemas (e.g., containing conventional suppository bases). In addition to the formulations described above, the compounds can also be formulated as depot preparations. Such long-acting formulations can be administered by injection (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or can be formulated as sparingly soluble derivatives, e.g., as a sparingly soluble salt.
[0147] In particular, the compounds disclosed herein can be administered orally, bucally or sublingually in the form of tablets containing excipients such as starch or lactose, or in capsules or ovoids, alone or in mixture with excipients, or in the form of elixirs or suspensions containing flavorings or colorings. Such liquid preparations can be prepared with pharma- ceutically acceptable additives, such as suspending agents. The compounds can also be injected parenterally, for example, intravenously, intramuscularly, subcutaneously or intracoronarily. For parenteral administration, the compounds are most often used in the form of a sterile aqueous solution, which may contain other substances, such as salts or sugar alcohols, such as mannitol or glucose, to make the solution isotonic with blood.
[0148] For veterinary use, the compounds disclosed herein are administered in an appropriately acceptable formulation in accordance with normal veterinary practice, and a veterinarian can readily determine the most appropriate dosing regimen and route of administration for a particular animal.
[0149] In some embodiments, all the components required for the treatment of KRAS-related disorders can be packaged in a kit, using the compounds disclosed herein alone or in combination with another drug or intervention conventionally used for the treatment of such diseases.Specifically, the present invention provides a kit for use in the treatment of disease, comprising a compound disclosed herein and a drug, including buffers and other components for preparing a deliverable form of said drug, and / or an apparatus for delivering such a drug, and / or any drug used in combination therapy with the compound disclosed herein, and / or a packaged set of instructions for the treatment of the disease packaged with the drug.The instructions can be fixed on any tangible medium, such as printed paper or computer-readable magnetic or optical media, or can be instructions that refer to a remote computer data source, such as a World Wide Web page accessible via the Internet.
[0150] "Therapeutically effective amount" refers to an amount effective to treat, prevent progression, or alleviate existing symptoms of the subject being treated. Determining an effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein. In general, "therapeutically effective dose" refers to the amount of a compound that produces a desired effect. For example, in a preferred embodiment, a therapeutically effective amount of a compound disclosed herein reduces KRAS activity by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% compared to a control.
[0151] The amount of compound to be administered may depend on the subject to be treated, the subject's age, health, sex and weight, type of concurrent treatment (if any), severity of disease, the nature of the desired effect, the mode and frequency of treatment, and the prescribing physician's judgment. The frequency of administration may also depend on the pharmacodynamic effect on arterial oxygen pressure. However, the most preferred dosage can be adjusted for each subject, as can be understood and determined by those skilled in the art without undue experimentation. This usually involves adjusting the standard dosage (e.g., reducing the dosage if the patient is underweight).
[0152] Although individual needs vary, determining the optimal range of effective amounts of the compounds is within the skill of the art. For administration to humans in the therapeutic or prophylactic treatment of the conditions and disorders identified herein, for example, typical dosages of the compounds of the present invention may be about 0.05 mg / kg / day to about 50 mg / kg / day, such as at least 0.05 mg / kg, at least 0.08 mg / kg, at least 0.1 mg / kg, at least 0.2 mg / kg, at least 0.3 mg / kg, at least 0.4 mg / kg, or at least 0.5 mg / kg, and preferably 50 mg / kg or less, 40 mg / kg or less, 30 mg / kg or less, 20 mg / kg or less, or 10 mg / kg or less, which may be, for example, about 2.5 mg / day (0.5 mg / kg x 5 kg) to about 5000 mg / day (50 mg / kg x 100 kg). For example, the dosage of the compound may be from about 0.1 mg / kg / day to about 50 mg / kg / day, from about 0.05 mg / kg / day to about 10 mg / kg / day, from about 0.05 mg / kg / day to about 5 mg / kg / day, from about 0.05 mg / kg / day to about 3 mg / kg / day, from about 0.07 mg / kg / day to about 3 mg / kg / day, from about 0.09 mg / kg / day to about 3 mg / kg / day, from about 0.05 mg / kg / day to about 0.1 mg / kg / day, about 0.1 mg / kg / day to about 1 mg / kg / day, about 1 mg / kg / day to about 10 mg / kg / day, about 1 mg / kg / day to about 5 mg / kg / day, about 1 mg / kg / day to about 3 mg / kg / day, about 3 mg / day to about 500 mg / day, about 5 mg / day to about 250 mg / day, about 10 mg / day to about 100 mg / day, about 3 mg / day to about 10 mg / day, or about 100 mg / day to about 250 mg / day. Such doses may be administered in a single dose or may be divided into multiple doses.
[0153] How to Use KRAS G12C Inhibitors The present disclosure provides a method for inhibiting RAS-mediated cell signaling, comprising contacting a cell with an effective amount of one or more compounds disclosed herein. Inhibition of RAS-mediated signaling can be assessed and demonstrated by a wide variety of methods known in the art. Non-limiting examples include: (a) a decrease in the GTPase activity of RAS; (b) a decrease in GTP binding affinity or an increase in GDP binding affinity; (c) an increase in Koff of GTP or a decrease in Koff of GDP; (d) a decrease in the level of downstream signaling molecules of the RAS pathway, such as a decrease in pMEK, pERK or pAKT levels; and / or (e) a decrease in the binding of the RAS complex to downstream signaling molecules, including but not limited to Raf. Kits and commercially available assays can be utilized to determine one or more of the above.
[0154] The present disclosure also provides methods of using a compound or pharmaceutical composition of the present disclosure to treat a disease condition, including, but not limited to, a condition caused by a G12C KRAS, HRAS, or NRAS mutation (e.g., cancer).
[0155] In some embodiments, a method of treating cancer is provided, comprising administering to a subject in need thereof an effective amount of any of the aforementioned pharmaceutical compositions comprising a compound disclosed herein. In some embodiments, the cancer is mediated by KRAS, HRAS, or NRAS G12C mutations. In various embodiments, the cancer is pancreatic cancer, colon cancer, or lung cancer. In some embodiments, the cancer is gallbladder cancer, thyroid cancer, and bile duct cancer.
[0156] In some embodiments, the disclosure provides a method of treating a disorder in a subject in need thereof, the method comprising determining whether the subject has a KRAS, HRAS or NRAS G12C mutation, and administering to the subject a therapeutically effective amount of at least one compound disclosed herein, or a pharma- ceutical acceptable salt thereof, if the subject is determined to have a KRAS, HRAS or NRAS G12C mutation.
[0157] The disclosed compounds have the potential to inhibit anchorage-independent cell growth and thus inhibit tumor metastasis. Thus, in another embodiment, the present disclosure provides a method for inhibiting tumor metastasis, comprising administering an effective amount of a compound disclosed herein.
[0158] KRAS, HRAS or NRAS G12C mutations have also been identified in hematological malignancies (e.g., cancers affecting the blood, bone marrow and / or lymph nodes). Accordingly, certain embodiments relate to the administration (e.g., in the form of a pharmaceutical composition) of the disclosed compounds to patients in need of treatment for hematological malignancies. Such malignancies include, but are not limited to, leukemias and lymphomas. For example, the disclosed compounds can be used to treat diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMoL) and / or other leukemias. In other embodiments, the compounds are useful for treating lymphomas, such as all subtypes of Hodgkin's lymphoma or non-Hodgkin's lymphoma. In various embodiments, the compounds are useful in the treatment of plasma cell malignancies such as multiple myeloma, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.
[0159] Determining whether a tumor or cancer contains a G12C KRAS, HRAS or NRAS mutation can be performed by evaluating the nucleotide sequence encoding the KRAS, HRAS or NRAS protein, by evaluating the amino acid sequence of the KRAS, HRAS or NRAS protein, or by evaluating the characteristics of a putative KRAS, HRAS or NRAS mutant protein. The sequence of wild-type human KRAS, HRAS or NRAS is known in the art (e.g., Accession No. NP203524).
[0160] Methods for detecting mutations in KRAS, HRAS or NRAS nucleotide sequences are known to those skilled in the art. These methods include, but are not limited to, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay, polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) assay, real-time PCR assay, PCR sequencing, mutant allele-specific PCR amplification (MASA) assay, direct sequencing, primer extension reaction, electrophoresis, oligonucleotide ligation assay, hybridization assay, TaqMan assay, SNP genotyping assay, high-resolution melting assay and microarray analysis. In some embodiments, samples are evaluated for G12C KRAS, HRAS or NRAS mutations by real-time PCR. In real-time PCR, a fluorescent probe specific for KRAS, HRAS or NRAS G12C mutation is used. If a mutation is present, the probe binds and fluorescence is detected. In some embodiments, KRAS, HRAS, or NRAS G12C mutations are identified using direct sequencing of specific regions in the KRAS, HRAS, or NRAS gene (e.g., exon 2 and / or exon 3). This technique identifies all possible mutations in the region that is sequenced.
[0161] Methods for detecting mutations in KRAS, HRAS or NRAS proteins are known to those skilled in the art, including, but not limited to, detection of KRAS, HRAS or NRAS mutants using binding agents (e.g., antibodies) specific for the mutant proteins, protein electrophoresis and Western blotting, and direct peptide sequencing.
[0162] The method of determining whether a tumor or cancer contains a G12C KRAS, HRAS or NRAS mutation can use a variety of samples. In some embodiments, the sample is taken from a subject with a tumor or cancer. In some embodiments, the sample is a fresh tumor / cancer sample. In some embodiments, the sample is a frozen tumor / cancer sample. In some embodiments, the sample is a formalin-fixed paraffin-embedded sample. In some embodiments, the sample is a circulating tumor cell (CTC) sample. In some embodiments, the sample is processed into a cell lysate. In some embodiments, the sample is processed into DNA or RNA.
[0163] The present disclosure also relates to a method of treating a hyperproliferative disorder in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound disclosed herein, or a pharma- ceutically acceptable salt thereof.In some embodiments, the method is directed to treating acute myeloid leukemia, adolescent cancer, childhood adrenocortical carcinoma, AIDS-related cancers (e.g., lymphoma and Kaposi's sarcoma), anal cancer, appendix cancer, astrocytoma, atypical teratoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial tumor, Burkitt's lymphoma, carcinoid tumor, atypical teratoma, embryonal tumor, germ cell tumor, primary lymphoma, cervical cancer, childhood cancer, chordoma, cardiac tumor, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative disorder. , colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, extrahepatic ductal carcinoma in situ (DCIS), germinoma, CNS cancer, endometrial cancer, ependymoma, esophageal cancer, nasal neuroblastoma, Ewing's sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, eye cancer, fibrous histiocytoma of bone, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, cardiac tumor, liver cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumor, pancreatic neuroendocrine tumor, kidney cancer, laryngeal cancer, Lip and oral cavity cancer, liver cancer, lobular carcinoma in situ (LCIS), lung cancer, lymphoma, metastatic squamous neck cancer of unknown primary, midline duct cancer, oral cavity cancer, multiple endocrine neoplasia syndrome, multiple myeloma / plasmacytoma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasms, multiple myeloma, Merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma and osteosarcoma of bone, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oral cavity cancer, lip and oral cavity cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer , papillomatosis, paraganglioma, paranasal sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, gastric cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, T-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, trophoblastic tumor, childhood anomalies, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer or virus-induced cancer.In some embodiments, the methods relate to the treatment of non-cancerous hyperproliferative disorders such as benign hyperplasia of the skin (eg, psoriasis), restenosis, or prostate (eg, benign prostatic hyperplasia (BPH)).
[0164] In some embodiments, the method of treatment relates to treating lung cancer, the method comprising administering an effective amount of any of the above compounds (or pharmaceutical compositions comprising same) to a subject in need thereof. In certain embodiments, the lung cancer is non-small cell lung cancer (NSCLC), such as adenocarcinoma, squamous cell lung cancer, or large cell lung cancer. In some embodiments, the lung cancer is small cell lung cancer. Other lung cancers treatable by the disclosed compounds include, but are not limited to, ductal tumors, carcinoid tumors, and anaplastic carcinomas.
[0165] The present disclosure further provides a method of modulating the activity of a G12C mutant KRAS, HRAS, or NRAS protein by contacting the protein with an effective amount of a compound of the present disclosure. Modulation can inhibit or activate the activity of the protein. In some embodiments, the present disclosure provides a method of inhibiting the activity of a protein by contacting a G12C mutant KRAS, HRAS, or NRAS protein with an effective amount of a compound of the present disclosure in solution. In some embodiments, the present disclosure provides a method of inhibiting the activity of a G12C mutant KRAS, HRAS, or NRAS protein by contacting a cell, tissue, or organ expressing the protein of interest. In some embodiments, the present disclosure provides a method of inhibiting the activity of a protein in a subject, including but not limited to rodents and mammals (e.g., humans), by administering an effective amount of a compound of the present disclosure to the subject. In some embodiments, the percentage of modulation is greater than 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In some embodiments, the percent inhibition is greater than 25%, 30%, 40%, 50%, 60%, 70%, 80% or 90%.
[0166] In some embodiments, the present disclosure provides a method of inhibiting the activity of KRAS, HRAS or NRAS G12C in a cell by contacting the cell with a compound of the present disclosure in an amount sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the cell. In some embodiments, the present disclosure provides a method of inhibiting the activity of KRAS, HRAS or NRAS G12C in a tissue by contacting the tissue with a compound of the present disclosure in an amount sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the tissue. In some embodiments, the present disclosure provides a method of inhibiting the activity of KRAS, HRAS or NRAS G12C in an organ by contacting the organ with a compound of the present disclosure in an amount sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the organ. In some embodiments, the present disclosure provides a method of inhibiting the activity of KRAS, HRAS or NRAS G12C in an animal by contacting the animal with a compound of the present disclosure in an amount sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the animal. In some embodiments, the present disclosure provides a method of inhibiting the activity of KRAS, HRAS or NRAS G12C in a mammal by contacting the mammal with a compound of the present disclosure in an amount sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the mammal. In some embodiments, the present disclosure provides a method of inhibiting the activity of KRAS, HRAS or NRAS G12C in a human by contacting the human with a compound of the present disclosure in an amount sufficient to inhibit the activity of KRAS, HRAS or NRAS G12C in the human. The present disclosure provides a method of treating a disease mediated by KRAS, HRAS or NRAS G12C activity in a subject in need of such treatment.
[0167] Combination therapy: The present disclosure also provides a method of combination therapy in which overlapping sets of agents known to regulate other pathways or other components of the same pathway or even target enzymes are used in combination with the compounds of the present disclosure or pharma- ceutically acceptable salts thereof. In one aspect, such treatments include, but are not limited to, the combination of one or more compounds of the present disclosure with chemotherapeutic agents, therapeutic antibodies, and radiation therapy to provide synergistic or additive therapeutic effects.
[0168] Currently, many chemotherapeutic agents are known in the art and can be used in combination with the compounds of the present disclosure. In some embodiments, the chemotherapeutic agent is selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antihormones, angiogenesis inhibitors, and antiandrogens. Non-limiting examples are chemotherapeutic agents, cytotoxic agents and non-peptide small molecules (e.g., Gleevec® (imatinib mesylate), Kyprolis® (carfilzomib), Velcade® (bortezomib), Casodex (bicalutamide), Iressa® (gefitinib), and adriamycin, as well as a host of chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM®); alkylsulfonates such as busulfan, improsulfan, and piposulfan; benzodopa, carboquone, metholedopa, cyclosulfonates ... aziridines such as cyclopentasiloxane and uredopa; ethylenimines and methylameramines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobembitine, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine;Aclacinomycin, Actinomycin, Ausramycin, Azaserine, Bleomycin, Cactinomycin, Calicheamicin, Carabicin, Carminomycin, Carzinophilin, Casodex™, Chromomycin, Dactinomycin, Daunorubicin, Detorubicin, 6-Diazo-5-oxo-L-norleucine, Doxorubicin, Epirubicin, Esorubicin, Idarubicin, Marcellomycin, Mitomycin, Mycophenolic acid, Nogalamycin, Olivomycin, Peplomycin, Potofilomycin, Puromycin Antibiotics such as cefotaxime, chelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, and trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, and enolate. Pyrimidine analogues such as citabine and floxiridine; androgens such as calcineurone, dromostanol propionate, epithiostanol, mepitiostane, and testolactone; antiadrenal drugs such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as floric acid; aceglatone; aldophosphamide glycosides; aminolevulinic acid; amsacrine; bestravcil; bisantrene; edatraxate; defofamine; demecolcine; diazicon; elfornithine; elliptinium acetate; etoglucide; gallium nitrate; hydroxy Urea;Lentinan;Lonidamine;Mitoguazone;Mitoxantrone;Mopidamol;Nitracrine;Pentostatin;Fenameth;Pirarubicin;Podophyllic acid;2-Ethylhydrazide;Procarbazine;PSK;Razoxane;Sizofiran;Spirogermanium;Tenuazonic acid;Triaziquone;2,2',2''-Trichlorotriethylamine;Urethane;Vindesine;Dacarbazine;Mannomustine;Mitobronitol;Mitolactol;Pipobroman;Gacytosine;Arabinoside ("Ara-C");Cyclophosphamide;Thiotepa;Taxanes such as paclitaxel and docetaxel; retinoic acid; esperamycin; capecitabine; pharmaceutically acceptable salts, acids or derivatives of any of the above;
[0169] Also included as suitable chemotherapy cell conditioners are those that act to regulate or inhibit hormone action on tumors, such as tamoxifen, (Nolvadex™), raloxifene, aromatase-inhibiting 4(5)-imidazole, 4-hydroxytamoxifen, trioxyphene, ketoxifene, LY. 117018, antihormonal agents such as antiestrogens including onapristone and toremifene (Fareston); and antiandrogens such as flutamide, nilutamide, bicalutamide, luprolide and goserelin; and chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogues such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; camptothecin-11 (CPT-11); the topoisomerase inhibitor RFS 2000; and difluoromethylornithine (DMFO).
[0170] Optionally, the compounds or pharmaceutical compositions of the present disclosure are selected from the group consisting of Herceptin®, Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex®, Taxotere®, ABVD, AVICINE, abagovomab, acridine carboxamide, adecatumab, 17-N-arylamino-17-demethoxygeldanamycin, alpharazine, alvocidib, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, amonafide, anthracenedione, amonafod, anthracenedione, anti-CD22 immunotoxin, antitumor, antitumor herbs, apaziquone, atiprimod, azathioprine, belotecan, bendamustine, BIBW 2992, biricoderm, brostallicin, bryostatin, buthionine sulfoximine, CBV (chemotherapy), calyculin, cell cycle non-specific antitumor agent, dichloroacetic acid, discodamolide, elsamitrucin, enocitabine, epothilone, eribulin, everolimus, exatecan, exisulind, ferruginol, forodesine, fosphestrol, ICE chemotherapy regimen, IT-101, imexon, imiquimod, indolocarbazole, irofulven, laniquidar, larotaxel, lenalidomide, lucantone, rutotecan, mafosfamide, mitozolomide, naf It may be used in combination with commonly prescribed anticancer drugs such as oxyzine, nedaplatin, olaparib, ortataxel, PAC-1, pawpaw, pixantrone, proteasome inhibitors, rebeccamycin, resiquimod, rubitecan, SN-38, salinosporamide A, sapatitabine, Stanford V, swainsonine, talaporfin, tariquidar, tegafur-uracil, temodar, tesetaxel, triplatin tetranitrate, tris(2-chloroethyl)amine troxacitabine, uramustine, vadimezan, vinflunine, ZD6126 or zosuquidar.
[0171] The present disclosure further relates to a method of using a compound or pharmaceutical composition provided herein in combination with radiation therapy to inhibit abnormal cell growth or treat hyperproliferative disorders in a mammal. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The administration of the compound disclosed herein in this combination therapy can be determined as described herein.
[0172] Radiation therapy can be administered by one or a combination of several methods, including, but not limited to, external beam therapy, internal radiation therapy, implant radiation, stereotactic radiosurgery, total body radiation therapy, radiotherapy, and permanent or temporary interstitial brachytherapy. The term "brachytherapy" as used herein refers to radiation therapy delivered by spatially confined radioactive material inserted into the body at or near the site of a tumor or other proliferative tissue disease. The term is intended to include, but is not limited to, exposure to radioisotopes (e.g., At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm153, Bi-212, P-32, and radioisotopes of Lu). Suitable radiation sources for use as cell conditioners of the present disclosure include both solid and liquid. As non-limiting examples, the radiation source can be a radionuclide such as I-125, I-131, Yb-169, Ir-192, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma rays, or other therapeutic rays. The radioactive material can be a fluid made from any solution of the radionuclide, for example a solution of I-125 or I-131, or the radioactive fluid can be produced using a slurry of a suitable fluid containing microparticles of a solid radionuclide such as Au-198, Y-90, etc. Additionally, the radionuclide can be embodied as a gel or radioactive microspheres.
[0173] The compounds or pharmaceutical compositions of the present disclosure may be used in combination with an amount of one or more substances selected from antiangiogenic agents, signal transduction inhibitors, antiproliferative agents, glycolytic inhibitors, or autophagy inhibitors. Antiangiogenic agents such as MMP-2 (matrix metalloproteinase 2) inhibitors, MMP-9 (matrix metalloproteinase 9) inhibitors, and COX-11 (cyclooxygenase 11) inhibitors may be used with the disclosed compounds and pharmaceutical compositions described herein.
[0174] Anti-angiogenic agents include, for example, rapamycin, temsirolimus (CCI-779), everolimus (RAD001), sorafenib, sunitinib, and bevacizumab. Examples of useful COX-II inhibitors include alecoxib, valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO 96 / 33172, WO 96 / 27583, EP 0818442, EP 1004578, WO 98 / 07697, WO 98 / 03516, WO 98 / 34918, WO 98 / 34915, WO 98 / 33768, WO 98 / 30566, EP 606046, EP 931788, and the like. No. 5,863,949, U.S. Pat. No. 5,861,510, and EP 0,780,386, all of which are incorporated herein by reference in their entireties. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferably, they selectively inhibit MMP-2 and / or AMP-9 relative to other matrix metalloproteinases (i.e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).Some specific examples of MMP inhibitors useful in the present disclosure are AG-3340, RO32-3555, and RS13-0830.
[0175] The compounds of the present invention include acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestine, ARGLABIN, arsenic trioxide, BAM002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA3030 (Dong-A), daclizumab, denileukin. Diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docosanol, doxercalciferol, doxifluridine, doxorubicin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon alpha, daunorubicin, doxorubicin, tretinoin, edelfosine, edrecolomab, efornithine, emiteflu, epirubicin, epoetin beta, etoposide phosphate, exemestane, exisulind, fadrozole, filgrastim, finasteride, f Dorabine phosphate, formestane, fotemustine, gallium nitrate, gemcitabine, gemtuzumabzogamicin, dimeracil / oteracil / tegafur combination, glycopin, goserelin, heptaplatin, human chorionic gonadotropin, human fetal alpha fetoprotein, ibandronate, idarubicin, (imiquimod, interferon alpha, interferon alpha, natural, interferon alpha-2, interferon alpha-2a, interferon alpha-2b, interferon alpha-N1, interferon alpha-n3, interferon alfacon-1, interferon alpha, natural, interferon beta, interferon beta-1a, interferon beta-1b, interferon gamma, natural interferon gamma-1a, natural interferon gamma-1b, interleukin-1 beta, iobenguane, irinotecan, irsogladine, lanreotide, LC9018 (Yakult), leflunomide, lenograstim, lentinan sulfate, letrozole, leucocyte alpha interferon, leuprorelin,Levamisole + fluorouracil, liarozole, lobaplatin, lonidamine, lovastatin, masoprocol, melasoprol, metoclopramide, mifepristone, miltefosine, millimostim, mismatched double-stranded RNA, mitoguazone, mitolactol, mitoxantrone, molgramostim, nafarelin, naloxone + pentazocine, nartograstim, nedaplatin, nilutamide, noscapine, novel erythropoiesis-stimulating protein, NSC 631570Octreotide, oprelvekin, osaterone, oxaliplatin, paclitaxel, pamidronate, pegaspargase, peginterferon alpha-2b, pentosan polysulfate sodium, pentostatin, picibanil, pirarubicin, rabbit antithymocytoma polyclonal antibody, polyethylene glycol interferon alpha-2a, porfimer sodium, raloxifene, raltitrexed, rasbriembodiment, rheniumRe 186Etidronate, RIIretinamide, rituximab, romurtide, samarium (153 Sm) Lexidonam, Sargramotim, Sizofiran, Sobuzoxane, Sonermin, Strontium-89 chloride, Suramin, Tasonermin, Tazarotene, Tegafur, Temoporfin, Temozolomide, Teniposide, Tetrachlorodecaoxide, Thalidomide, Thymalfasin, Thyrotropin alpha, Topotecan, Toremifene, Tositumomab-Iodine 131, Trastuzumab, Treosulfan, Tretinoin, Trilostane, Trimetrexate, Triptorelin, Tumor necrosis factor alpha, Natural, Ubenimex Bladder cancer vaccine, Maruyama vaccine, Melanoma lysate vaccine, Bal Bicine, verteporfin, vinorelbine, VIRULIZIN, zinostatin stimalamer or zoledronic acid; abarelix; AE941 (Aeterna), ambamustine, antisense oligonucleotides, bcl-2 (Genta), APC8015 (Dendreon), cetuximab, decitabine, dexaminoglutethimide, diazicon, EL532 (Elan), EM800 (Endorecherche), eniluracil, etanidazole, fenretinide, filgrastim SD01 (Amgen), fulvestrant, galocitabine, gastrin 17 immunogen,HLA-B7 gene therapy (Vical), granulocyte-macrophage colony-stimulating factor, histamine dihydrochloride, ibritumomab tiuxetan, ilomastat, IM862 (Cytran), interleukin-2, iproxifen, LDI200 (Milkhaus), religistim, lintuzumab, CA125MAb (Biomira), cancer MAb (Nihon Yakuhin Kaihatsu Co., Ltd.), HER-2 and Fc MAb (Medarex), idiotypic 105AD7MAb (CRC Technology), idiotypic CEA MAb (Trilex), LYM-1-iodine 131 MAb (Techniclone), polymorphic epithelial mucin yttrium 90 MAb (Antisoma), marimastat, menogaril, mitumomab, motexafine gadolinium, MX6 (Galderma), nelarabine, nolatrexed, P30 protein, pegvisomant, pemetrexed, porfiromycin, prinomastat, RL 0903 (Shire), rubitecan, satraplatin, sodium phenylacetate, sparfosic acid, SRL 172 (SR Pharma), SU 5416 (SUGEN), TA 077 (Tanabe), tetrathiomolybdate, thaliblastine, thrombopoietin, tin ethyl etiopurpurin, tirapazamine, cancer vaccine (Biomira), melanoma vaccine (New York University), melanoma vaccine (Sloan Kettering It may also be used in combination with other anti-cancer drugs such as rivaroxaban (New York Medical College), melanoma oncolysate vaccine (Royal Newcastle Hospital), viral melanoma lysate vaccine (Royal Newcastle Hospital) or valspodar.
[0176] The compounds of the present invention may further be used together with VEGFR inhibitors.Other compounds described in the following patents and patent applications may be used in combination therapy: U.S. Pat. No. 6,258,812, U.S. Patent Application Publication No. 2003 / 0105091, WO 01 / 37820, U.S. Pat. No. 6,235,764, WO 01 / 32651, U.S. Pat. No. 6,630,500, U.S. Pat. No. 6,515,004, U.S. Pat. No. 6,713,485, U.S. Pat. No. 5,521,184, U.S. Pat. No. 5,770,599, U.S. Pat. No. 5,747,498, WO 02 / 02 / 01, and the like. / 68406, 02 / 66470, 02 / 55501, 04 / 05279, 04 / 07481, 04 / 07458, 04 / 09784, 02 / 59110, 99 / 45009, 00 / 59509, 99 / 61422, U.S. Patent No. 5,990,141, WO 00 / 12089 and WO 00 / 02871.
[0177] In some embodiments, the combination comprises a composition of the present invention in combination with at least one antiangiogenic agent.Agents include, but are not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen-binding regions, radionuclides, and combinations and conjugates thereof.Agents may be agonists, antagonists, allosteric regulators, toxins, or more generally act to inhibit or stimulate their targets (e.g., activate or inhibit receptors or enzymes), thereby promoting cell death or halting cell proliferation.
[0178] Exemplary anti-angiogenesis agents include ERBITUX™ (IMC-C225), KDR (kinase domain receptor) inhibitors (e.g., antibodies and antigen binding regions that specifically bind to kinase domain receptors), anti-VEGF agents (e.g., antibodies or antigen binding regions that specifically bind to VEGF or a soluble VEGF receptor or its ligand binding region) such as AVASTIN™ or VEGF-TRAP™, and anti-VEGF receptor drugs (e.g., antibodies or antigen binding regions that specifically bind to), EGFR inhibitors (e.g., antibodies or antigen binding regions that specifically bind to), such as Vectibix (panitumumab), IRESSA™ (gefitinib), TARCEVA™ (erlotinib), anti-Ang1 and anti-Ang2 agents (e.g., antibodies or antigen binding regions that specifically bind to them or their receptors, e.g., Tie2 / Tek), and anti-Tie2 kinase inhibitors (e.g., antibodies or antigen binding regions that specifically bind to them). The pharmaceutical compositions of the invention may also include one or more agents (e.g., antibodies, antigen-binding regions, or soluble receptors) that specifically bind and inhibit the activity of a growth factor, such as antagonists and antibodies or antigen-binding regions of hepatocyte growth factor (HGF, also known as scatter factor) that specifically bind to the receptor "c-met."
[0179] Other anti-angiogenic agents include Campath, IL-8, B-FGF, Tek antagonists (Ceretti et al., U.S. Patent Application Publication No. 2003 / 0162712; U.S. Patent No. 6,413,932), anti-TWEAK agents (e.g., antibodies or antigen binding regions that specifically bind or soluble TWEAK receptor antagonists; Wiley, U.S. Patent No. 6,727,225), ADAM disintegrin domains that antagonize the binding of integrins to their ligands (Fanslow et al., U.S. Patent Application Publication No. 2002 / 0042368), anti-ep h-receptor and / or anti-ephrin antibodies or antigen binding regions (see U.S. Pat. Nos. 5,981,245; 5,728,813; 5,969,110; 6,596,852; 6,232,447; 6,057,124 and members of their patent families), and anti-PDGF-BB antagonists (e.g., antibodies or antigen binding regions that specifically bind) as well as antibodies or antigen binding regions that specifically bind to PDGF-BB ligands and PDGFR kinase inhibitors (e.g., antibodies or antigen binding regions that specifically bind thereto).
[0180] Further anti-angiogenic / anti-tumor agents include: SD-7784 (Pfizer, USA); cilengitide (Merck KGaA, Germany, EPO 770622); pegaptanib octasodium, (Gilead Sciences, USA); Alphastatin, (BioActa, UK); M-PGA, (Celgene, USA, U.S. Pat. No. 5,712,291); ilomastat, (Arriva, USA, U.S. Pat. No. 5,892,112); emaxanib, (Pfizer, USA, U.S. Pat. No. 5,792,783); vatalanib, (Novartis, Switzerland); 2-methoxyestradiol, (EntreMed, USA); TLC ELL-12, (Elan, Ireland); anecortave acetate, (Alcon, USA); alpha-D148 Mab, (Amgen, USA); CEP-7055, (Cephalon, USA); Anti-Vn Mab, (Crucell, Netherlands) DAC: Antiangiogenic agent, (ConjuChem, Canada); Angiocidin, (InKine Pharmaceutical, USA); KM-2550, (Kyowa Hakko, Japan); SU-0879, (Pfizer, USA); CGP-79787, (Novartis, Switzerland, European Patent No. 970070); ARGENT technology, (Ariad, USA); YIGSR-Stealth, (Johnson&Johnson, USA); Fibrinogen E fragment, (BioActa, UK); Angiogenesis inhibitor, (Trigen, UK); TBC-1635, (Encysive Pharmaceuticals, USA);SC-236, (Pfizer, USA);ABT-567, (Abbott, USA);metastatin, (EntreMed, USA);angiogenesis inhibitor, (Tripep, Sweden);maspin, (Sosei Group Corporation, Japan);2-methoxyestradiol, (Oncology Sciences Corporation, USA);ER-68203-00, (IVAX, USA);Benefin, (Lane Labs, USA);Tz-93, (Tsumura & Co., Japan); TAN-1120, (Takeda Pharmaceutical Co., Japan); FR-111142, (Fujisawa Pharmaceutical Co., Japan, JP02233610); Platelet factor 4, (RepliGen, USA, EP 407122); Vascular endothelial growth factor antagonist, (Borean, Denmark); Bevacizumab (pINN), (Genentech, USA); Angiogenesis inhibitor, (SUGEN, USA); XL 784, (Exelixis, USA); XL 647, (Exelixis, USA); MAb, alpha 5 beta 3 integrin, 2nd generation, (Applied Molecular Evolution, USA and MedImmune, USA); Gene therapy, retinopathy, (Oxford BioMedica, UK); Enzastaurin hydrochloride (USAN), (Lilly, USA); CEP 7055, (Cephalon, USA and Sanofi-Synthelabo, France);BC1, (Genoa Institute of Cancer Research, Italy);angiogenesis inhibitor, (Alchemia, Australia);VEGF antagonist, (Regeneron, USA);rBPI 21 and BPI-derived antiangiogenic agents, (XOMA, USA);PI 88, (Progen, Australia);cilengitide (pINN), (Merck KGaA, German; Munich Technical University, Germany, Scripps Clinic and Research Foundation, USA);cetuximab (INN), (Aventis, France);AVE 8062, (Ajinomoto Co., Japan);AS 1404, (Cancer Research Laboratory, New Zealand);SG 292, (Telios, USA);endostatin, (Boston Children's Hospital, USA);ATN 161, (Attenuon, USA);angiostatin, (Boston Children's Hospital, USA);2-methoxyestradiol, (Boston Children's Hospital, USA);ZD 6474, (AstraZeneca, UK);ZD 6126, (Angiogene Pharmaceuticals, UK); PPI 2458, (Praecis, USA); AZD 9935, (AstraZeneca, UK); AZD 2171, (AstraZeneca, UK); Vatalanib (pINN), (Novartis, Switzerland and Schering AG, Germany); Tissue factor pathway inhibitor, (EntreMed, USA); Pegaptanib (Pinn), (Gilead Sciences, USA); Xanthorrhizol, (Yonsei University, South Korea); Gene-based vaccine, VEGF-2, (Scripps Clinic and Research Foundation, USA); SPV5.2, (Supratek, Canada); SDX 103, (University of California at San Diego, USA); PX 478, (ProlX, USA); Metastatin, (EntreMed, USA); Troponin I, (Harvard University, USA);SU 6668, (SUGEN, USA);OXI 4503, (OXiGENE, USA);o-guanidine, (Dimensional Pharmaceuticals, USA);motuporamine C, (British Columbia University, Canada);CDP 791, (Celltech Group, UK);atiprimod (pINN), (GlaxoSmithKline, UK);E 7820, (Eisai Co., Ltd., Japan);CYC 381, (Harvard University, USA);AE 941, (Aeterna, Canada);vaccine, angiogenesis, (EntreMed, USA);urokinase plasminogen activator inhibitor, (Dendreon, USA);oglufanide (pINN), (Melmotte, USA);HIF-1 alpha inhibitor, (Xenova, UK);CEP 5214, (Cephalon, USA);BAY RES 2622, (Bayer, Germany); Angiocidin, (InKine, USA); A6, (Angstrom, USA);KR 31372, (Korea Research Institute of Chemical Technology, South Korea); GW 2286, (GlaxoSmithKline, UK); EHT 0101, (ExonHit, France); CP 868596, (Pfizer, USA); CP 564959, (OSI, USA); CP 547632, (Pfizer, USA); 786034, (GlaxoSmithKline, UK); KRN 633 (Kirin Brewery Co., Ltd., Japan); Drug delivery system, intraocular, 2-methoxyestradiol, (EntreMed, USA); Anginex, (Maastricht University, Netherlands and University of Minnesota, USA); ABT 510, (Abbott, USA); AAL 993, (Novartis, Switzerland);VEGI, (ProteomTech, USA);Tumor necrosis factor-alpha inhibitor, (National Institute on Aging, USA);SU 11248, (Pfizer, USA and SUGEN USA);ABT 518, (Abbott, USA);YH16, (Yantai Rongchang, China);S-3APG, (Boston Children's Hospital, USA and EntreMed, USA);MAb, KDR, (ImClone Systems, USA);MAb, alpha5beta1, (Protein Design, USA);KDR kinase inhibitor, (Celltech Group, UK and Johnson & Johnson, USA);GFB 116, (University of South Florida, USA and Yale University, USA);CS 706, (Sankyo, Japan);Combretastatin A4 prodrug, (Arizona State University, USA); chondroitinase AC, (IBEX, Canada); BAY RES 2690, (Bayer, Germany); AGM 1470, (Harvard University, USA, Takeda Pharmaceutical Co., Ltd., Japan and TAP, USA); AG 13925, (Agouron, USA);Tetrathiomolybdate, (University of Michigan, USA);GCS 100, (Wayne State University, USA)CV 247, (Ivy Medical, UK);CKD 732, (Chong Kun Dang, South Korea);MAb, Vascular Endothelial Growth Factor, (Xenova, UK);Irsogladine (INN), (Nippon Shinyaku Co., Ltd., Japan);RG 13577, (Aventis, France);WX 360, (Wilex, Germany);Squalamine (pINN), (Genaera, USA);RPI 4610, (Sirna, USA);Cancer Therapy, (Marinova, Australia);Heparanase Inhibitor, (InSight, Israel);KL 3106, (Kolon, South Korea);Honokiol, (Emory University, USA);ZK CDK, (Schering AG, Germany);ZK Angio, (Schering AG, Germany); ZK 229561, (Novartis, Switzerland and Schering AG, Germany); XMP 300, (XOMA, USA); VGA 1102, (Taisho, Japan); VEGF receptor modulator, (Pharmacopeia, USA); VE-cadherin-2 antagonist, (ImClone Systems, USA); vasostatin, (National Institutes of Health, USA); vaccine, Flk-1, (ImClone Systems, USA); TZ 93, (Tsumura Corporation, Japan); tumstatin, (Beth Israel Hospital, USA); cleaved soluble FLT1 (vascular endothelial growth factor receptor 1), (Merck&Co, USA); Tie-2 ligand, (Regeneron, USA); and thrombospondin 1 inhibitor, (Allegheny Health, Education and Research Foundation, USA).
[0181] Autophagy inhibitors include, but are not limited to, chloroquine, 3-methyladenine, hydroxychloroquine (Plaquenil™), bafilomycin A1, 5-amino-4 imidazolecarboxamide riboside (AICAR), okadaic acid, autophagy-inhibiting algal toxins that inhibit type 2A or type 1 protein phosphatases, analogs of cAMP and drugs that increase cAMP levels, such as adenosine, LY204002, N6-mercaptopurine riboside, and vinblastine. Additionally, antisense or siRNA that inhibit the expression of proteins, including, but not limited to, ATG5 (involved in autophagy), may also be used.
[0182] Further pharma- ceutically active compounds / agents that may be used in the treatment of cancer and may be used in combination with one or more compounds of the present invention include epoetin alfa; darbepoetin alfa; panitumumab; pegfilgrastim; palifermin; filgrastim; denosumab; ancestim; AMG 102; AMG 386; AMG 479; AMG 655; AMG 745; AMG 951; and AMG 706 or a pharma- ceutically acceptable salt thereof.
[0183] In certain embodiments, the compositions provided herein are administered in combination with a chemotherapeutic agent. Suitable chemotherapeutic agents include natural products such as vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (e.g., etoposide and teniposide), antibiotics (e.g., dactinomycin (actinomycin D), daunorubicin, doxorubicin, and idarubicin), anthracyclines, mitoxantrone, bleomycin, plicamycin (mithramycin), mitomycin, enzymes (e.g., L-asparagine systemically administered), and the like. L-asparaginase, which metabolizes asparagine to remove cells that do not have the ability to synthesize their own asparagine; antiplatelet agents; antiproliferative / antimitotic alkylating agents such as nitrogen mustards (e.g., mechlorethamine, cyclophosphamide and analogs, melphalan and chlorambucil); ethylenimines and methylmelamines (e.g., hexamethylmelamine and thiotepa); CDK inhibitors (e.g., seliciclib, UCN-01, P1446A-05, PD-0332991, dinaciclib, , P27-00, AT-7519, RGB286638 and SCH727965), alkylsulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine (BCNU) and analogs and streptozocin), trazene-dacarbazine (DTIC), folate analogs (e.g., methotrexate), antiproliferative / antimitotic antimetabolites, pyrimidine analogs (e.g., fluorouracil, floxuridine and cytarabine), purine analogs and related inhibitors (e.g., mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine), aromatase inhibitors (e.g., anastrozole, exemestane and letrozole) and platinum coordination complexes (e.g., cisplatin and carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide, histone deacetylase (HDAC) inhibitors (e.g., trichostatin, sodium butyrate, apicidan, suberoylanilide hydroxamic acid apicidan, vorinostat, LBH589, romidepsin, ACY-1215, and panobinostat), mTor inhibitors (e.g., temsirolimus, everolimus, ridafololimus, and sirolimus), KSP (Eg5) inhibitors (e.g., Array 520), DNA binders (e.g., Zalipsis), PI3K delta inhibitors (e.g., GS-1101 and TGR-1202), PI3K delta and gamma inhibitors (e.g., CAL-130), multikinase inhibitors (e.g., TG02 and sorafenib), hormones (e.g., estrogen), and hormonal agonists such as luteinizing hormone releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide, and triptorelin). agonists, BAFF neutralizing antibodies (e.g., LY2127399), IKK inhibitors, p38MAPK inhibitors, anti-IL-6 (e.g., CNTO328), telomerase inhibitors (e.g., GRN163L), Aurora kinase inhibitors (e.g., MLN8237), cell surface monoclonal antibodies (e.g., anti-CD38 (HUMAX-CD38), anti-CS1 (e.g., elotuzumab), HSP90 inhibitors (e.g., 17AAG and KOS 953), P13K / Akt inhibitors (e.g., Perifosine), Akt inhibitors (e.g., GSK-2141795), PKC inhibitors (e.g., Enzastaurin), FTIs (e.g., Zarnestra™), anti-CD138 (e.g., BT062), Torc1 / 2 specific kinase inhibitors (e.g., INK128), kinase inhibitors (e.g., GS-1101), ER / UPR targeting agents (e.g., MKC-3946), cFMS Inhibitors (e.g., ARRY-382), JAK1 / 2 inhibitors (e.g., CYT387), PARP inhibitors (e.g., olaparib and veliparib (ABT-888)), and BCL-2 antagonists. Other chemotherapeutic agents may include mechlorethamine, camptothecin, ifosfamide, tamoxifen, raloxifene, gemcitabine, navelbine, sorafenib, or any analog or derived variant of the above.
[0184] The compounds of the present invention may also be used in combination with radiation therapy, hormone therapy, surgery, and immunotherapy, all of which are well known to those skilled in the art.
[0185] In certain embodiments, the compositions provided herein are administered in combination with a steroid. Suitable steroids include 21-acetoxypregnolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximethasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandre The therapeutically active agents may include, but are not limited to, cyclosporine ... Examples of drugs that can be used to treat nausea include dronabinol; granisetron; metoclopramide; ondansetron; and prochlorperazine; or pharma- ceutically acceptable salts thereof.
[0186] The compounds of the present invention may also be used in combination with additional pharmacologic active compounds that interrupt or inhibit RAS-RAF-ERK or PI3K-AKT-TOR signaling pathways. In other such combinations, the additional pharmacologic active compounds are PD-1 and PD-L1 antagonists. The compounds or pharmaceutical compositions of the present disclosure may also be used in combination with an amount of one or more substances selected from EGFR inhibitors, MEK inhibitors, PI3K inhibitors, AKT inhibitors, TOR inhibitors, Mcl-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors, proteasome inhibitors, and immunotherapies including monoclonal antibodies, immunomodulatory imids (IMiDs), anti-PD-1, anti-PDL-1, anti-CTLA4, anti-LAG1 and anti-OX40 agents, GITR agonists, CAR-T cells, and BiTEs.
[0187] EGFR inhibitors include, but are not limited to, small molecule antagonists, antibody inhibitors, or specific antisense nucleotides or siRNAs. Useful antibody inhibitors of EGFR include cetuximab (Erbitux), panitumab (Vectibix), zalutumumab, nimotuzumab, and matuzumab. Small molecule antagonists of EGFR include gefitinib, erlotinib (Tarceva), and recently lapatinib (TykerB). See, e.g., Yan L, et.al., Pharmacogenetics and Pharmacogenomics In Oncology Therapeutic Antibody Development, BioTechniques 2005;39(4):565-8 and Paez JG, et.al., EGFR Mutations In Lung Cancer Correlation With Clinical Response To Gefitinib Therapy, Science 2004;304(5676):1497-500.
[0188] Non-limiting examples of small molecule EGFR inhibitors include any of the EGFR inhibitors described in the following patent publications and all pharma- ceutically acceptable salts and solvates of said EGFR inhibitors: EP 520722, published December 30, 1992; EP 566226, published October 20, 1993; WO 96 / 33980, published October 31, 1996; U.S. Patent No. 5,747,498, published May 5, 1998; U.S. Patent No. 5,747,498, published October 3, 1996; WO 96 / 30347 published on 2006-08-19; EP 787772 published on 06-08-1997; WO 97 / 30034 published on 21-08-1997; WO 97 / 30044 published on 21-08-1997; WO 97 / 38994 published on 23-10-1997; WO 97 / 49688 published on 31-12-1997; EP 837063 published on 22-04-1998 WO 98 / 02434 published January 22, 1998; WO 97 / 38983 published October 23, 1997; WO 95 / 19774 published July 27, 1995; WO 95 / 19970 published July 27, 1995; WO 97 / 13771 published April 17, 1997; WO 98 / 02437 published January 22, 1998; WO 97 / 38983 published October 23, 1997; WO 98 / 02438, published on September 12, 1997; WO 97 / 32881, published on September 12, 1997; German Patent Application DE 19629652, published on January 29, 1998; WO 98 / 33798, published on August 6, 1998; WO 97 / 32880, published on September 12, 1997; WO 97 / 32880, published on September 12, 1997; European Patent Application Publication No. 682027, published on November 15, 1995;WO 97 / 02266, published January 23, 1997; WO 97 / 27199, published July 31, 1997; WO 98 / 07726, published February 26, 1998; WO 97 / 34895, published September 25, 1997; WO 96 / 31510', published October 10, 1996; WO 98 / 14449, published April 9, 1998; WO 98 / 14450, published April 9, 1998; WO 98 / 14451, published April 9, 1998; WO 95 / 0, published April 13, 1995 No. 9847; WO 97 / 19065 published May 29, 1997; WO 98 / 17662 published April 30, 1998; U.S. Patent No. 5,789,427 issued August 4, 1998; U.S. Patent No. 5,650,415 issued July 22, 1997; U.S. Patent No. 5,656,643 issued August 12, 1997; WO 99 / 35146 published July 15, 1999; WO 99 / 35132 published July 15, 1999; WO 99 / 07701 published February 18, 1999 and WO 92 / 20642 published November 26, 1992. Further non-limiting examples of small molecule EGFR inhibitors include any of the EGFR inhibitors described in Traxler, P., 1998, Exp. Opin. Ther. Patents 8(12):1599-1625.
[0189] Antibody-based EGFR inhibitors include any anti-EGFR antibody or antibody fragment that can partially or completely block EGFR activation by its natural ligand. Non-limiting examples of antibody-based EGFR inhibitors include those described in Modjtahedi, H., et al., 1993, Br. J. Cancer 67:247-253; Teramoto, T., et al., 1996, Cancer 77:639-645; Goldstein et al., 1995, Clin. Cancer Res. 1:1311-1318; Huang, SM, et al., 1999, Cancer Res. 15:59(8):1935-40; and Yang, X., et al., 1999, Cancer Res. 59:1236-1243. Thus, the EGFR inhibitor can be the monoclonal antibody Mab E7.6.3 (Yang, 1999, supra) or Mab C225 (ATCC Accession No. HB-8508), or an antibody or antibody fragment having the binding specificity thereof.
[0190] MEK inhibitors include, but are not limited to, CI-1040, AZD6244, PD318088, PD98059, PD334581, RDEA119, ARRY-142886, ARRY-438162, and PD-325901.
[0191] PI3K inhibitors include wortmannin, the 17-hydroxywortmannin analogs described in WO 06 / 044453, 4-[2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine (also known as GDC 0941, described in WO 09 / 036,082 and WO 09 / 055,730), 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile (BEZ 235 or NVP-BEZ 235, described in WO 06 / 122806), (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one, described in WO 2008 / 070740, LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, available from Axon Medchem), PI 103 hydrochloride (3-[4-(4-morpholinylpyrido-[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol hydrochloride, available from Axon Medchem), PIK 75 (Axon N'-[(1E)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylene]-N,2-dimethyl-5-nitrobenzenesulfono-hydrazide hydrochloride available from Medchem, PIK 90 (N-(7,8-dimethoxy-2,3-dihydro-imidazo[1,2-c]quinazolin-5-yl)-nicotinamide available from Axon Medchem), GDC-0941 bismesylate (2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate), AS-252424 (5-[1-[5-(4-fluoro-2-hydroxy-phenyl)-furan-2-yl]-meth-(Z)-ylidene]-thiazolidine-2,4-dione available from Axon Medchem) and TGX-221 (7-methyl-2-(4-morpholinyl)-9-[1-(phenylamino)ethyl]-4H-pyrido-[1,2-a]pyrimidin-4-one available from Axon Medchem), XL-765 and XL-147. Other PI3K inhibitors include demethoxyviridin, perifosine, CAL101, PX-866, BEZ235, SF1126, INK1117, IPI-145, BKM120, XL147, XL765, Palomid 529, GSK1059615, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, PI-103, GNE-477, CUDC-907 and AEZS-136.
[0192] AKT inhibitors include Akt-1-1 (inhibits Akt1) (Barnett et al. (2005) Biochem. J., 385 (Pt. 2), 399-408); Akt-1-1,2 (inhibits Ak1 and 2) (Barnett et al. (2005) Biochem. J. 385 (Pt. 2), 399-408); API-59CJ-Ome (e.g., Jin et al. (2004) Br. J. Cancer 91, 1808-12); 1-H-imidazo[4,5-c]pyridinyl compounds (e.g., WO 05011700); indole-3-carbinol and its derivatives (e.g., U.S. Pat. No. 6,656,963; Sarkar and Li (2004) J Nutr. 134 (12 Suppl), 3493S-3498S); perifosine (e.g., interferes with membrane localization of Akt; Dasmahapatra et al. (2004) Clin. Cancer Res. 10(15), 5242-52, 2004); phosphatidylinositol ether lipid analogs (e.g., Gills and Dennis (2004) Expert. Opin. Investig. Drugs 13, 787-97); and triciribine (TCN or API-2 or NCI identifier: NSC 154020; Yang et al. (2004) Cancer Res. 64, 4394-9).
[0193] TOR inhibitors include, but are not limited to, inhibitors including AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1 / TORC2 inhibitors (including PI-103, PP242, PP30 and torin1). Other TOR inhibitors at the FKBP12 enhancer; rapamycin and its derivatives including: CCI-779 (temsirolimus), RAD001 (everolimus; WO 9409010) and AP23573; rapalogs such as those disclosed in WO 98 / 02441 and WO 01 / 14387, such as AP23573, AP23464 or AP23841; 40-(2-hydroxybutyric acid) inhibitors such as 4-hydroxybutyric acid; diethyl)rapamycin, 40-[3-hydroxy(hydroxymethyl)methylpropanoate]-rapamycin (also known as CC1779), 40-epi-(tetrazolito)-rapamycin (also known as ABT578), 32-deoxorapamycin, 16-pentynyloxy-32(S)-dihydrorapamycin and other derivatives disclosed in WO 05005434; U.S. Pat. No. 5,258,389, WO 94 / 09 No. 0101, WO 92 / 05179, U.S. Pat. No. 5,118,677, U.S. Pat. No. 5,118,678, U.S. Pat. No. 5,100,883, U.S. Pat. No. 5,151,413, U.S. Pat. No. 5,120,842, WO 93 / 111130, WO 94 / 02136, WO 94 / 02485, WO 95 / 14023 FRET, derivatives disclosed in WO 94 / 02136, WO 95 / 16691, WO 96 / 41807, WO 96 / 41807 and U.S. Pat. No. 5,256,790; phosphorus-containing rapamycin derivatives (e.g., WO 05016252); 4H-1-benzopyran-4-one derivatives (e.g., U.S. Provisional Patent Application No. 60 / 528,340).
[0194] MCl-1 inhibitors include, but are not limited to, AMG-176, MIK665 and S63845.Myeloid cell leukemia-1 (MCL-1) protein is one of the important anti-apoptotic members of B-cell lymphoma-2 (BCL-2) protein family.Overexpression of MCL-1 is closely related to tumor progression and resistance to not only conventional chemotherapy but also targeted therapy, including BCL-2 inhibitors such as ABT-263.
[0195] SHP inhibitors include, but are not limited to, SHP099.
[0196] Proteasome inhibitors include, but are not limited to, Kyprolis® (carfilzomib), Velcade® (bortezomib), and oprozomib.
[0197] Immunotherapies include, but are not limited to, anti-PD-1 agents, anti-PDL-1 agents, anti-CTLA-4 agents, anti-LAG1 agents, and anti-OX40 agents.
[0198] Monoclonal antibodies include, but are not limited to, Darazalex® (daratumumab), Herceptin® (trastuzumab), Avastin® (bevacizumab), Rituxan® (rituximab), Lucentis® (ranibizumab), and Eylea® (aflibercept).
[0199] Immunomodulatory agents (IMiDs) are a class of immunomodulatory drugs (drugs that modify the immune response) that contain an imide group. The IMiD class includes thalidomide and its analogs (lenalidomide, pomalidomide, and apremilast).
[0200] Exemplary anti-PD-1 antibodies and their methods of use are described in Goldberg et al., Blood 110(1):186-192 (2007), Thompson et al., Clin. Cancer Res. 13(6):1757-1761 (2007), and Korman et al., International Application No. PCT / JP2006 / 309606 (WO 2006 / 121168 A1), each of which is expressly incorporated herein by reference. These include: Yervoy™ (ipilimumab) or tremelimumab (against CTLA-4), galiximab (against B7.1), BMS-936558 (against PD-1), MK-3475 (against PD-1), AMP224 (against B7DC), BMS-936559 (against B7-H1), MPDL3280A (against B7-H1), MEDI-570 (against ICOS), AMG557 (against B7H2), MGA271 (against B7H3), IMP321 (against LAG-3), BMS-663513 (against CD137), PF-05082566 (against CD137), CDX-1127 (against CD27), anti-OX40 (Providence Health Services), huMAbOX40L (against OX40L), atacicept (against TACI), CP-870893 (against CD40), lucatumumab (against CD40), decatuzumab (against CD40), muromonab-CD3 (against CD3), ipilumumab (against CTLA-4). Immunotherapies also include engineered T cells (e.g., CAR-T cells) and bispecific antibodies (e.g., BiTEs).
[0201] In certain embodiments, the compounds of the invention are used in combination with an anti-PD-1 antibody. In certain embodiments, the anti-PD-1 antibody (or antigen-binding antibody fragment thereof) comprises one, two, three, four, five, or all six of the CDR amino acid sequences of SEQ ID NOs: 1-6 (presented in this order: HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3). In certain embodiments, the anti-PD-1 antibody (or antigen-binding antibody fragment thereof) comprises all six of the CDR amino acid sequences of SEQ ID NOs: 1-6. In other embodiments, the anti-PD-1 antibody (or antigen-binding antibody fragment thereof) comprises (a) a heavy chain variable region amino acid sequence in SEQ ID NO: 7 or a variant sequence thereof that differs in only one or two amino acids or has at least or about 70% sequence identity, or (b) a light chain variable region amino acid sequence in SEQ ID NO: 8 or a variant sequence thereof that differs in only one or two amino acids or has at least or about 70% sequence identity. In an exemplary embodiment, the anti-PD-1 antibody (or antigen-binding antibody fragment thereof) comprises the heavy chain variable region amino acid sequence in SEQ ID NO: 7 and the light chain variable region amino acid sequence in SEQ ID NO: 8. In other embodiments, the anti-PD-1 antibody (or antigen-binding antibody fragment thereof) comprises (a) the heavy chain amino acid sequence of SEQ ID NO: 9, or a variant sequence thereof which differs in only one or two amino acids or has at least or about 70% sequence identity; or (b) the light chain amino acid sequence of SEQ ID NO: 10, or a variant sequence thereof which differs in only one or two amino acids or has at least or about 70% sequence identity. In an exemplary embodiment, the anti-PD-1 antibody (or antigen-binding antibody fragment thereof) comprises the heavy chain amino acid sequence of SEQ ID NO: 9 and the light chain variable region amino acid sequence of SEQ ID NO: 10.
[0202] The disclosure further provides nucleic acid sequences encoding anti-PD-1 antibodies (or antigen-binding portions thereof). In exemplary embodiments, the antibodies comprise one, two, three, four, five, or all six CDRs encoded by the nucleic acids of SEQ ID NOs: 11-16 (presented in this order: HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3). In another exemplary embodiment, the antibodies comprise all six CDRs encoded by the nucleic acids of SEQ ID NOs: 11-16. In some embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) comprises (a) a heavy chain variable region encoded by SEQ ID NO: 17 or a variant sequence thereof that differs in only 1, 2, 3, 4, 5, or 6 nucleic acids or has at least or about 70%, 85%, 90%, or 95% sequence identity, or (b) a light chain variable region encoded by SEQ ID NO: 18 or a variant sequence thereof that differs in only 1, 2, 3, 4, 5, or 6 nucleic acids or has at least or about 70%, 85%, 90%, or 95% sequence identity. In an exemplary embodiment, the anti-PD-1 antibody (or antigen-binding portion thereof) comprises a heavy chain variable region encoded by SEQ ID NO: 17 and a light chain variable region encoded by SEQ ID NO: 18. In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) comprises (a) a heavy chain encoded by SEQ ID NO: 19, or a variant sequence thereof that differs in only 1, 2, 3, 4, 5, or 6 nucleic acids or has at least or about 70%, 85%, 90%, or 95% sequence identity, or (b) a light chain encoded by SEQ ID NO: 20, or a variant sequence thereof that differs in only 1, 2, 3, 4, 5, or 6 nucleic acids or has at least or about 70%, 85%, 90%, or 95% sequence identity. In an exemplary embodiment, the anti-PD-1 antibody (or antigen-binding portion thereof) comprises a heavy chain encoded by SEQ ID NO: 19 and a light chain encoded by SEQ ID NO:20.
[0203] GITR agonists include GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as those described in U.S. Pat. No. 6,111,090box.c, EP 090505B1, U.S. Pat. No. 8,586,023, WO 2010 / 003118 and WO 2011 / 090754, or those described in, for example, U.S. Pat. No. 7,025,962, EP 1947183B1, U.S. Pat. No. 7,812,135, U.S. Pat. No. 8,388,967, U.S. Pat. No. 8,591,886, EP 1866339, WO 201 Examples of anti-GITR antibodies include, but are not limited to, those described in WO 1 / 028683, WO 2013 / 039954, WO 2005 / 007190, WO 2007 / 133822, WO 2005 / 055808, WO 99 / 40196, WO 2001 / 03720, WO 99 / 20758, WO 2006 / 083289, WO 2005 / 115451, U.S. Patent No. 7,618,632, and WO 2011 / 051726.
[0204] The compounds described herein may be used in combination with the drugs disclosed herein or other suitable drugs depending on the condition being treated. Thus, in some embodiments, one or more compounds of the present disclosure will be co-administered with the other drugs described above. When used in combination therapy, the compounds described herein are administered simultaneously or separately with the second drug. This combination administration may include simultaneous administration of the two drugs in the same dosage form, simultaneous administration of separate dosage forms, and separate administration. That is, the compounds described herein and any of the drugs described above can be formulated together in the same dosage form and administered simultaneously. Alternatively, the compounds of the present disclosure and any of the drugs described above can be administered simultaneously, where both drugs are in separate formulations. In another alternative, the compounds of the present disclosure can be administered followed by any of the drugs described above, or in the reverse order. In some embodiments of the separate administration protocol, the compounds of the present disclosure and any of the drugs described above are administered within minutes, or within hours, or within days.
[0205] As one aspect of the present invention contemplates treating a disease / condition with a combination of pharma- ceutically active compounds that can be administered separately, the present invention further relates to combining separate pharmaceutical compositions in the form of a kit. The kit comprises two separate pharmaceutical compositions: a compound of the present invention and a second pharmaceutical compound. The kit comprises a container for housing the separate compositions, such as a divided bottle or a divided foil pouch. Other examples of containers include syringes, boxes and bags. In some embodiments, the kit comprises instructions for use of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), administered at different dosage intervals or when dosage of the individual components of the combination is desired by the prescribing medical professional. EXAMPLES
[0206] Example 1 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one, 5 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one, 6 The absolute configurations of 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one and 13(M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one were assigned based on co-crystallization. The absolute configurations of intermediates C and G were assigned based on co-crystallization of molecules prepared from these intermediates, such as in Examples 1, 5, 6 and 13.
[0207] Example 1 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0208] Step 1: 2,5,6-Trichloronicotinamide (Intermediate A). 1,1'-Carbonyldiimidazole (40 g, 247 mmol) was added in portions to 2,5,6-trichloronicotinic acid (50.7 g, 224 mmol, Combi-Blocks, San Diego, CA) in THF (400 mL) such that gas evolution ceased during the addition. The resulting mixture was stirred for 5 min, then degassed with house vacuum and flushed with nitrogen. The resulting mixture was heated to 50° C. for 60 min, then diluted with toluene (100 mL) and concentrated to half of the original volume. The resulting mixture was cooled to 0° C. and ammonium hydroxide (60 mL, 437 mmol) was added slowly via syringe. The reaction was stirred at room temperature for 10 min, diluted with EtOAc (200 mL) and washed with water (3×100 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was suspended in 9:1 heptane / EtOAc (300 mL) and filtered. The filtered solid was collected and the remaining mother liquor was partially evaporated to half the original volume, cooled to 0° C., and filtered. The two crops of filtered solid were combined to give 2,5,6-trichloronicotinamide.
[0209] Step 2: 2-Isopropyl-4-methylpyridin-3-amine (Intermediate B). To a slurry of 3-amino-2-bromo-4-picoline (360 mg, 1.9 mmol, Combi-Blocks, San Diego, CA) in TFH (4 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (Sigma-Aldrich, St.Loius, MO) (79 mg, 0.10 mmol). The resulting slurry was degassed with argon for 2 minutes, followed by the addition of 2-propylzinc bromide (0.5 M solution in THF, 5.40 mL, 2.7 mmol, Sigma-Aldrich, St.Loius, MO). The resulting solution was heated at 60° C. for 17 hours, then the heat was removed and the reaction was allowed to cool to room temperature. The reaction mixture was quenched with water (10 mL) and 1N NaOH solution (20 mL), followed by extraction with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent: 0-15% MeOH / DCM) to give 2-isopropyl-4-methylpyridin-3-amine. 1 H NMR(400MHz,DMSO-d6)δ ppm 7.66(d,J=4.6Hz,1H),6.78(d,J=4.8Hz,1H),4.72(br s,2H),3.14-3.25(m,1H),2.08(s,3H),1.14(d,J=6.8Hz,6H).m / z(ESI, cation):151.1(M+H) + .
[0210] Step 3: 2,5,6-trichloro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide. To a -78°C slurry of 2,5,6-trichloronicotinamide (Intermediate A, 3.10 g, 13.8 mmol) in THF (46 mL) was added oxalyl chloride (2 M solution in DCM, 7.4 mL, 14.7 mmol) slowly via syringe. The resulting slurry was heated at 60°C for 3.5 h, then the heat was removed and the reaction was cooled to -78°C. Triethylamine (6.0 mL, 42.6 mmol) was added via cannula followed by a solution of 2-isopropyl-4-methylpyridin-3-amine (Intermediate B, 2.12 g, 14.1 mmol). The resulting slurry was allowed to warm to room temperature and stirred for 1 h, then partitioned between water (120 mL) and EtOAc (175 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated in vacuum. The residue was suspended in 9:1 heptane / EtOAc and filtered. The filtered solid was collected to give 2,5,6-trichloro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide. 1 H NMR(400MHz,DMSO-d6)δ ppm 11.31(s,1H),9.54(s,1H),8.66(s,1H),8.34(d,J=4.8Hz,1H),7.16(d,J=5.0Hz,1H) ,3.24-3.33(m,1H),2.22(s,3H),1.17(d,J=6.6Hz,6H).m / z(ESI, cation):400.9(M+H) + .
[0211] Step 4: (M)-6,7-Dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate C). To an ice-cold solution of 2,5,6-trichloro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (4.71 g, 11.7 mmol) in THF (55 mL) was added KHMDS (1 M solution in THF, 23.5 mL, 23.5 mmol) slowly via syringe. After 10 min, the ice bath was removed and the resulting solution was stirred at room temperature for an additional 30 min. The reaction was quenched with saturated aqueous ammonium chloride solution (125 mL) and extracted with EtOAc (250 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent: 0-11% MeOH / DCM) to give 6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione as a mixture of atropisomers. 1 H NMR(400MHz,DMSO-d6)δ ppm 12.27(br s,1H),8.59(s,1H),8.52(d,J=5.0Hz,1H),7.28(d,J=5.0Hz,1H),2.82-2.92(m,1H),2 .04(s,3H),1.08(d,J=6.6Hz,3H),1.01(d,J=6.8Hz,3H).m / z(ESI, cation):365.0(M+H) + .
[0212] The mixture of 6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione atropisomers (55.1 g) was purified by SFC (AD, 250 × 50 mm, 5 μm, 50% MeOH / CO2, 180 g / min, 102 bar) to give two peaks: Peak 1 ((P)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 22.1 g, >99% ee) and peak 2 ((M)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 23.2 g, >99% ee).
[0213] Step 5: (M)-6-Chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate D). A mixture of (M)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate C, 4.40 g, 12.1 mmol), (2-fluorophenyl)boronic acid (2.53 g, 18.1 mmol; Combi-Blocks, San Diego, CA), KOAc (9.46 g, 96 mmol) and (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.882 g, 1.21 mmol) in 1,4-dioxane (57 mL) / water (1.7 mL) was aerated with nitrogen and then stirred for 2 h at 90° C. Additional (2-fluorophenyl)boronic acid (0.5 g) was added and the reaction mixture was stirred for an additional 15 min. The reaction mixture was diluted with EtOAc (200 mL), added to a separatory funnel and washed with water (2×100 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product was adsorbed onto silica and purified by silica gel chromatography (silica gel, 0-100% EtOAc / heptane) to give (M)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (4.03 g, 9.49 mmol, 79% yield) as a pale yellow foam. 1 H NMR(400MHz,CDCl3)δ 8.91(br s,1H)8.60(s,1H)8.50-8.55(m,1H)7.37-7.46(m,1H)7.06-7.17(m,4H)2.81(spt,J=6.7Hz,1H)2.10(s,3H)1.24(br d,J=6.8Hz,3H)1.09(br d,J=6.6Hz,3H). 19 F NMR(377MHz,CDCl3)δ -112.87(s,1F).m / z(ESI, cation):424.9(M+H) + .
[0214] Step 6: (2R,5S,M)-4-(6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate tert-butyl. A solution of (M)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2,4(1H,3H)-dione (Intermediate D, 1.08 g, 2.54 mmol), phosphoryl trichloride (0.284 mL, 3.05 mmol) and DIPEA (1.33 mL, 7.63 mmol) in acetonitrile (6 mL) was stirred at 80° C. for 30 min. The reaction mixture was removed from the heat block and (2R,5S)-1-Boc-2,5-dimethylpiperazine (0.545 g, 2.54 mmol; AstaTech Inc., Bristol, PA) and DIPEA (1.328 mL, 7.63 mmol) were added. The reaction mixture was stirred at room temperature for 15 min. The reaction mixture was diluted with EtOAc (100 mL), added to a separatory funnel and washed with saturated aqueous NaHCO3 (2 x 75 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product was adsorbed onto silica and purified by silica gel chromatography (eluent: 0-70% EtOAc-EtOH (3:1) / heptane) to give tert-butyl (2R,5S,M)-4-(6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a pale yellow solid (861 mg, 1.39 mmol, 55% yield). 11H NMR (400 MHz, CDCl3) δ 8.45 - 8.52 (m, 1H) 8.11 (s, 1H) 7.41 (br d, J = 5.4 Hz, 1H) 7.04 - 7.21 (m, 4H) 4.90 - 5.06 (m, 1H) 4.34 - 4.69 (m, 1H) 4.03 - 4.20 (m, 1H) 3.78 - 4.01 (m, 2H) 3.46 - 3.65 (m, 1H) 2.63 - 2.80 (m, 1H) 2.03 (br s, 3H) 1.52 (s, 9H) 1.25 - 1.31 (m, 6H) 1.23 (br d, J = 7.0 Hz, 3H) 1.08 (br d, J = 6.6 Hz, 3H). 19 19F NMR (377 MHz, CDCl3) δ -112.51 (br s, 1F). m / z (ESI, positive ion): 621.0 (M + H) + .
[0215] Step 7: 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A solution of (2R,5S,M)-4-(6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (0.861 g, 1.39 mmol) in 2,2,2-trifluoroacetic acid (11 mL, 140 mmol) was stirred at room temperature for 15 minutes. The reaction mixture was concentrated in vacuo. A solution of the resulting oil, DIPEA (0.724 mL, 4.16 mmol) and acryloyl chloride (0.5 M in DCM, 2.77 mL, 1.39 mmol) in DCM (7 mL) was stirred at room temperature for 15 min. The reaction mixture was diluted with EtOAc (100 mL), added to a separatory funnel and washed with saturated aqueous NaHCO3 (2 x 75 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product was adsorbed onto silica and purified by silica gel chromatography (eluent: 0-100% EtOAc-EtOH (3:1) / heptane) to give 4-((2S,5R.M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a pale yellow solid (562 mg, 4.93 mmol, 77% yield). 1H NMR(400MHz,CDCl3)δ 8.44-8.53(m,1H)8.11(s,1H)7.41(br d,J=6.2Hz,1H)7.04-7.22(m,4H)6.52-6.71(m,1H)6.40(br t,J=15.2Hz,1H)5.75-5.84(m,1H)5.02-5.21(m,1H)4.29-4.53(m,1H)3.46-4.09(m,4H)2.63-2.75(m,1H)2.03(br s,3H)1.39-1.49(m,3H)1.24-1.36(m,3H)1.23(br d,J=5.0Hz,3H)1.08(br d,J=6.2Hz,3H). 19 F NMR(377MHz,CDCl3)δ -112.52(s,1F),-112.48(s,1F).m / z(ESI, cation):574.8(M+H) + .
[0216] Example 2 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0217] Step 1: (2R,5S,M)-tert-butyl 4-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate. A 250 mL round bottom flask was charged with (M)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate C, 6.65 g, 18.2 mmol) and DIPEA (4.8 mL, 27.3 mmol) in acetonitrile (91 mL), followed by phosphorous oxychloride (2.6 mL, 27.3 mmol). The resulting mixture was stirred at 80° C. for 30 min and then concentrated in vacuo to give (M)-4,6,7-trichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a brown solid. The crude brown solid was used in the next step without further purification. m / z (ESI, positive): 383.0 (M+H). + .
[0218] To a mixture of (M)-4,6,7-trichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one and DIPEA (4.8 mL, 27.3 mmol) in DMF (50 mL) was added (2R,5S)-1-Boc-2,5-dimethylpiperazine (4.29 g, 20.03 mmol, AstaTech Inc., Bristol, PA) and the mixture was stirred at room temperature for 15 min. The mixture was added to ice water (80 mL) and stirred for 15 min. The resulting precipitate was collected by filtration, washed with water, and dried to give tert-butyl (2R,5S,M)-4-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a yellow solid (4.70 g, 8.37 mmol, 46.0% yield). The filtrate was extracted with EtOAc (2×100 mL). The combined organic extracts were dried over MgSO4. The solution was filtered and concentrated in vacuo to give additional title compound as a yellow solid (5.51 g, 9.81 mmol, 53.9% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 8.59(br d,J=4.8Hz,1H),8.54(s,1H),7.40(br d,J=2.7Hz,1H),4.87(br s,1H),4.23-4.44(m,1H),4.01-4.09(m,1H),3.95(br s,1H),3.73(br dd,J=13.7,2.5Hz,1H),3.46-3.65(m,1H),2.67-2.76(m,1H),2.04(s,3H),1.45 -1.57(m,9H),1.36(d,J=6.6Hz,3H),1.08-1.18(m,9H).m / z(ESI,positive):561.2(M+H) + .
[0219] Step 2: 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate E). To a solution of (2R,5S,M)-4-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-tert-butyl carboxylate (5.51 g, 9.81 mmol) in DCM (20 mL) was added trifluoroacetic acid (10 mL, 134 mmol) at room temperature and the mixture was stirred for 1 h. After the reaction was complete, the mixture was concentrated in vacuo to give (M)-6,7-dichloro-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. m / z (ESI, positive): 461.2 (M+H). + .
[0220] To the above (M)-6,7-dichloro-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one and N,N'-diisopropylethylamine (8.6 mL, 49.1 mmol) in DCM (20 mL) was added acryloyl chloride (0.8 mL, 9.81 mmol) at 0°C and the mixture was stirred for 1 h. The reaction mixture was diluted with DCM (50 mL) and washed with saturated ammonium chloride solution (50 mL). To the aqueous solution was added saturated sodium chloride (25 mL) and the mixture was extracted with DCM (50 mL x 2). The organic extracts were combined and dried over MgSO4. The solution was filtered and concentrated in vacuo to give a brown oil. The crude brown oil was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0–10% MeOH / DCM) to give (M)-4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a pale yellow foam (4.66 g, 9.04 mmol, 92% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 8.46-8.54(m,2H),7.30(d,J=5.0Hz,1H),6.82(ddd,J=16.5,14.0,10.5Hz,1H),6.18(dd,J=16.7,2.2H z,1H),5.74(dt,J=10.4,2.7Hz,1H),4.78-4.91(m,1H),4.39-4.75(m,1H),3.97-4.16(m,1H),3.94(br s,1H),3.83(br d,J=3.9Hz,1H),3.49(br dd,J=13.9,3.7Hz,1H),2.59-2.70(m,1H),1.97(s,3H),1.25-1.32(m,3H) ,1.09-1.20(m,3H),1.05(dd,J=11.4,6.6Hz,6H).m / z(ESI, positive):515.2(M+H) + .
[0221] Step 3: 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A 50 mL round bottom flask was charged with 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate E, 188 mg, 0.37 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (114 mg, 0.73 mmol, Combi-Blocks, San Diego, CA), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (27 mg, 0.04 mmol), KOAc (179 mg, 1.82 mmol) and 1,4-dioxane (4.0 mL) along with 2 drops of water. The reaction mixture was stirred at 90° C. for 18 h. The mixture was concentrated in vacuo. The crude product was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-10% EtOAc (with 10% MeOH) / heptane) to give 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (16 mg, 0.03 mmol, 7.4% yield) as a yellow solid. 1H NMR(400MHz,DMSO-d6)δ ppm 10.10(br d,J=17.6Hz,1H),8.44(br s,1H),8.38(d,J=4.8Hz,1H),7.10-7.31(m,2H),6.78-6.96(m,1H),6.59-6.75(m ,2H),6.20(dd,J=16.7,2.0Hz,1H),5.68-5.84(m,1H),4.78-4.88(m,1H),4.50(br d,J=1.7Hz,1H),4.08-4.29(m,2H),3.86(br d,J=9.1Hz,2H),2.61-2.80(m,1H),1.91(br s,3H),1.35(br d,J=6.4Hz,3H),1.18-1.30(m,3H),1.07(d,J=6.8Hz,3H),0.95(br d,J=6.4Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -115.82(br d,J=266.2Hz,1F).m / z(ESI,positive):591.2(M+H) + .
[0222] Example 3 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0223] A mixture of 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate E, 3.07 g, 5.96 mmol), tetrakis(triphenylphosphine)palladium (0.34 g, 0.30 mmol), (2-amino-6-fluorophenyl)boronic acid pinacol ester (1.55 g, 6.55 mmol, CombiPhos, Trenton, NJ) and sodium carbonate, anhydrous, powder (3.16 g, 29.8 mmol) in 1,4-dioxane (20 mL) / water (10 mL) was stirred at 90° C. for 40 minutes. To the resulting mixture was added water (25 mL) and the mixture was extracted with EtOAc (2×50 mL). The organic extracts were combined and dried over MgSO4. The solution was filtered and concentrated in vacuo to give the crude product as a yellow solid. The resulting crude product was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-10% EtOAc (with 10% MeOH) / heptane) to give 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (1.83 g, 3.09 mmol, 52.0% yield) as a yellow solid. 1H NMR(400MHz,DMSO-d6)δ ppm 8.43(s,1H),8.39(d,J=4.8Hz,1H),7.19(d,J=4.8Hz,1H),7.00-7.11(m,1H),6.82(br dd,J=16.6,10.6Hz,1H),6.45(d,J=8.3Hz,1H),6.27-6.35(m,1H),6.19(dd ,J=16.6,2.3Hz,1H),5.76(ddd,J=10.1,5.5,2.2Hz,1H),5.07-5.19(m,2H), 4.45-4.90(m,2H),3.47-4.24(m,4H),2.60-2.88(m,1H),1.85-1.99(m,3H), 1.30-1.39(m,3H),1.16-1.29(m,3H),1.03-1.11(m,3H),0.87-1.03(m,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -116.01--115.34(m,1F).m / z(ESI, positive):590.2(M+H) + .
[0224] Example 4 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0225] Step 1: 2,6-Dichloro-5-fluoronicotinamide (Intermediate F). To a mixture of 2,6-dichloro-5-fluoro-nicotinic acid (4.0 g, 19.1 mmol, AstaTech Inc., Bristol, PA) in DCM (48 mL) was added oxalyl chloride (2 M solution in DCM, 11.9 mL, 23.8 mmol) followed by a catalytic amount of DMF (0.05 mL). The reaction mixture was stirred at room temperature overnight and then concentrated in vacuo. The residue was dissolved in 1,4-dioxane (48 mL) and cooled to 0 °C. Ammonium hydroxide solution (28-30% NH3 mains, 3.6 mL, 28.6 mmol) was added slowly via syringe. The resulting mixture was stirred at 0 °C for 30 min and then concentrated. The residue was diluted with a 1:1 mixture of EtOAc / heptane and stirred for 5 min followed by filtration. The filtered solid was discarded and the remaining mother liquor was partially concentrated to half the original volume and filtered. The filtered solid was washed with heptane and dried overnight in a vacuum oven (45° C.) to give 2,6-dichloro-5-fluoronicotinamide. 1 H NMR(400MHz,DMSO-d6)δ ppm 8.23(d,J=7.9Hz,1H)8.09(br s,1H)7.93(br s,1H).m / z(ESI, cation):210.9(M+H) + .
[0226] Step 2: 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide. To an ice-cold slurry of 2,6-dichloro-5-fluoronicotinamide (Intermediate F, 5.0 g, 23.9 mmol) in THF (20 mL) was added oxalyl chloride (2 M solution in DCM, 14.4 mL, 28.8 mmol) slowly via syringe. The resulting mixture was heated at 75° C. for 1 h, then the heat was removed and the reaction was concentrated to half of the original volume. After cooling to 0° C., THF (20 mL) was added followed by a solution of 2-isopropyl-4-methylpyridin-3-amine (Intermediate B, 3.59 g, 23.92 mmol) in THF (10 mL) dropwise via cannula. The resulting mixture was stirred at 0° C. for 1 h, and then the reaction was quenched with a 1:1 mixture of brine and saturated aqueous ammonium chloride. The mixture was extracted with EtOAc, and the combined organic layers were dried over anhydrous Na2SO4 and concentrated to give 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide. This material was used in the subsequent step without further purification. m / z (ESI, positive ion): 385.1 (M+H). + .
[0227] Step 3: (M)-7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate G). To an ice-cold solution of 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (9.2 g, 24.0 mmol) in THF (40 mL) was added KHMDS (1 M solution in THF, 50.2 mL, 50.2 mmol) slowly via syringe. The ice bath was removed and the resulting mixture was stirred at room temperature for 40 min. The reaction was quenched with saturated aqueous ammonium chloride solution and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography (eluent: 0-50% EtOAc-EtOH (3:1) / heptane) to give 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione as a mixture of atropisomers. 1 H NMR(400MHz,DMSO-d6)δ ppm 12.27(br s,1H),8.48-8.55(m,2H),7.29(d,J=4.8Hz,1H),2.87(quin,J=6.6Hz,1H),1.99-2.06(m,3H),1.09(d,J=6.6Hz,3H),1.01(d,J=6.6Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ:-126.90(s,1F).m / z(ESI, cation):349.1(M+H) + .
[0228] The mixture of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione atropisomers (648 g) was purified by SFC (AD, 150 × 50 mm, 5 μm, 50% MeOH / CO2, 180 g / min, 102 bar) to give two peaks: peak 1 (P-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 230.6 g, >99% ee) and peak 2 ((M)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 227.8 g, 97.1% ee).
[0229] Step 4: (2R,5S,M)-tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (Intermediate H). To a solution of (M)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate G, 4.75 g, 13.62 mmol) in toluene (54.5 mL) was added DIPEA (4.76 mL, 27.2 mmol) followed by phosphorous oxychloride (2.54 mL, 27.2 mmol). The reaction was heated to 50° C. for 50 min. The reaction was concentrated in vacuo to give (M)-4,7-dichloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a brown solid which was used directly in the next step. m / z (ESI, positive): 367.0 (M+H). + .
[0230] To the crude (M)-4,7-dichloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was added DMF (113 mL) followed by tert-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate (2.92 g, 13.62 mmol, AstaTech Inc., Bristol, PA). To the solution was added DIPEA (11.9 mL, 68.1 mmol) dropwise with stirring. After stirring for 5 min, the reaction was diluted with water and EtOAc. The organic layer was diluted with 1M LiCl and brine, followed by drying over MgSO4. This material was purified by silica gel chromatography (eluent: 0-80% EtOAc:EtOH (3:1) / heptane) to give tert-butyl (2R,5S,M)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a yellow-orange solid (6.85 g, 12.57 mmol, 92% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 8.49(d,J=4.77Hz,1H)8.39(d,J=8.50Hz,1H)7.26(d,J=4.98Hz,1H)4.80(br s,1H)4.18-4.38(m,1H)3.99(br d,J=14.72Hz,1H)3.78-3.90(m,1H)3.64-3.73(m,1H)3.45-3.61(m,1H)2.60(dt,J=13.37,6.58Hz,1H)1.95(s,3H)1.45(s,9H)1.29(br d,J=6.63Hz,3H)1.11(br d,J=6.01Hz,3H)1.06(d,J=6.84Hz,3H)1.03(d,J=6.63Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -128.25(s,1F).m / z(ESI, positive):545.2(M+H) + .
[0231] Step 5: 4-(6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (2R,5S,M)-tert-butyl. A drum vial with a Teflon screw cap was charged with KOAc (0.330 g, 3.36 mmol). The vial was sealed and evacuated / backfilled with nitrogen. A solution of (2R,5S,M)-tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (Intermediate H, 0.366 g, 0.671 mmol) in dioxane (4.26 mL) was added, followed by water (0.2 mL). The reaction was heated to 90° C. for 2 minutes. Dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.049 g, 0.067 mmol, Strem Chemicals, Newburyport, MA) and (2-fluorophenyl)boronic acid (0.188 g, 1.343 mmol, Combi-Blocks, San Diego, CA) were added and the reaction was stirred at 90°C for 3 h. The reaction was cooled to room temperature and diluted with water and EtOAc. The organic phase was washed with brine, dried over MgSO4, and concentrated in vacuo. The crude residue was purified by silica gel flash chromatography (eluent: 0-60% EtOAc:EtOH (3:1) / heptane) to give tert-butyl (2R,5S,M)-4-(6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (0.336 g, 0.555 mmol, 83% yield) as a yellow solid. 1H NMR(400MHz,DMSO-d6)δ ppm 8.44(d,J=4.98Hz,1H)8.32(d,J=9.54Hz,1H)7.51-7.60(m,1H)7.26-7.38(m,3H)7.22(d,J=4.98Hz,1H)4.84(br s,1H)4.25-4.42(m,1H)4.12(br d,J=13.89Hz,1H)3.83(br d,J=12.44Hz,1H)3.65-3.75(m,1H)3.46-3.63(m,1H)2.70(dt,J=13.48,6.74Hz,1H)1.95(s,3H)1. 46(s,9H)1.33(d,J=6.63Hz,3H)1.16-1.20(m,3H)1.08(d,J=6.84Hz,3H)0.98(d,J=6.63Hz,3H).19F NMR(376MHz,DMSO-d6)δ ppm -113.72(m,1F)-129.04(m,1F).m / z(ESI,positive):605.2(M+H) + .
[0232] Step 6: 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. To a solution of (2R,5S,M)-4-(6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate tert-butyl (0.335 g, 0.554 mmol) in DCM (11.1 mL) was added trifluoroacetic acid (1.65 mL, 22.2 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo to give crude 4-((2S,5R,M)-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one, which was used without further purification.
[0233] The crude 4-((2S,5R,M)-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was dissolved in DCM (15 mL). DIPEA (0.484 mL, 2.77 mmol) was added followed by acryloyl chloride (1.1 M solution in DCM, 0.453 mL, 0.499 mmol). The reaction mixture was stirred for 5 min. The reaction mixture was concentrated in vacuo. The crude material was purified by silica gel chromatography (eluent: 20-80% EtOAc:EtOH (3:1) / heptane) to give 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (0.184 g, 0.329 mmol, 59.5% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 8.44(d,J=4.98Hz,1H)8.33-8.39(m,1H)7.52-7.60(m,1H)7.25-7.39(m,3H)7.23(d,J=4.77Hz,1H)6.77-6.93(m,1H)6. 14-6.26(m,1H)5.71-5.81(m,1H)4.11-4.97(m,4H)3.48-3.93(m,2H)2.71(td,J=6.27,3.63Hz,1H)1.95(s,3H)1.32(br t,J=7.26Hz,3H)1.17-1.28(m,3H)1.08(d,J=6.63Hz,3H)0.98(br d,J=6.63Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -113.88--113.54(m,1F)-129.19--128.86(m,1F).m / z(ESI, positive):559.2(M+H) + .
[0234] Example 5 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0235] Step 1: 4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (2R,5S,M)-tert-butyl. A dram vial with a Teflon screw cap was charged with KOAc (0.315 g, 3.21 mmol). The vial was capped and evacuated / backfilled with nitrogen. A solution of (2R,5S,M)-tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (Intermediate H, 0.35 g, 0.642 mmol) in dioxane (4.08 mL) was added, followed by water (0.2 mL). The reaction mixture was heated to 90° C. for 2 min. Dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.047 g, 0.064 mmol, Strem Chemicals, Newburyport, MA) and (2-fluoro-6-hydroxyphenyl)boronic acid (0.200 g, 1.28 mmol, Wuxi) were added and the reaction was stirred at 90°C for 3 h. The reaction was cooled to room temperature and diluted with water and EtOAc. The organic phase was washed with brine, dried over MgSO4 and concentrated in vacuo. The crude residue was purified by silica gel chromatography (eluent: 0-60% EtOAc-EtOH (3:1) / heptane) to give tert-butyl (2R,5S,M)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a yellow solid (0.375 g, 0.604 mmol, 94% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 10.19(br s,1H)8.39(d,J=4.77Hz,1H)8.26(d,J=8.91Hz,1H)7.24-7.32(m,1H)7.19(d,J=4.77Hz,1H )6.74(d,J=8.50Hz,1H)6.69(t,J=8.81Hz,1H)4.76-4.88(m,1H)4.26-4.44(m,1H)4.15(br d,J=14.30Hz,1H)3.76-3.84(m,1H)3.71(m,1H)3.41-3.66(m,1H)2.69(quin,J=6.63Hz,1H)1.91(s, 3H)1.46(s,9H)1.34(d,J=6.43Hz,3H)1.19(m,3H)1.07(d,J=6.43Hz,3H)0.95(d,J=6.84Hz,3H).19F NMR(376MHz,DMSO-d6)δ ppm -115.55(m,1F)-128.46(br s,1F).m / z(ESI,positive):621.2(M+H) + .
[0236] Step 2: 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. To a solution of (2R,5S,M)-4-(6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate tert-butyl (0.375 g, 0.604 mmol) in DCM (12.1 mL) was added trifluoroacetic acid (1.80 mL, 24.2 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo to give crude 4-((2S,5R,M)-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one, which was used without further purification.
[0237] The crude 4-((2S,5R,M)-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was dissolved in DCM (15 mL) and cooled to 0° C. N,N'-diisopropylethylamine (0.528 mL, 3.02 mmol) was added followed by dropwise addition of acryloyl chloride (1.1 M solution in DCM, 0.549 mL, 0.604 mmol). The reaction mixture was stirred for 5 min. The reaction mixture was concentrated in vacuo and the crude material was purified by silica gel chromatography (eluent: 0-80% EtOAc-EtOH (3:1) / heptane). The resulting product contained a small amount of bis-acylated (acylation of the phenolic hydroxy group in addition to the piperazine nitrogen) impurity. The material was treated with THF (3 mL) and 1N NaOH (0.6 mL). The reaction mixture was stirred for 15 min. The reaction was quenched with saturated ammonium chloride and the mixture was diluted with water and EtOAc. The organic phase was separated and the aqueous phase was extracted with additional EtOAc. The organic phases were combined, washed with brine, dried over MgSO4, and concentrated in vacuo to give 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (0.17 g, 0.296 mmol, 49.0% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 10.20(br s,1H)8.39(br d,J=4.35Hz,1H)8.26-8.32(m,1H)7.24-7.33(m,1H)7.19(br d,J=4.15Hz,1H)6.78-6.94(m,1H)6.65-6.77(m,2H)6.16-6.25(m,1H)5.73-5.82 (m,1H)4.10-4.94(m,4H)3.45-3.93(m,2H)2.65-2.75(m,1H)1.91(s,3H)1.33(br t,J=6.01Hz,3H)1.19-1.30(m,3H)1.07(br d,J=6.63Hz,3H)0.95(br d,J=5.80Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -115.59--115.51(m,1F)-128.49--128.38(m,1F).m / z(ESI, positive):575.2(M+H) + .
[0238] Example 6 4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0239] Step 1: 4-(7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (2R,5S,M)-tert-butyl. A dram vial equipped with a Teflon screw cap was charged with potassium carbonate (0.152 mL, 2.52 mmol), (2-amino-6-fluorophenyl)boronic acid pinacol ester (0.132 mL, 0.555 mmol, CombiPhos, Trenton, NJ), (2R,5S,M)-tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (Intermediate H, 0.275 g, 0.505 mmol) and tetrakis(triphenylphosphine)palladium (0.058 g, 0.050 mmol, Strem Chemicals, Newburyport, MA). The vial was capped and evacuated / backfilled with nitrogen. 1,4-Dioxane (1.68 mL) was added followed by water (0.841 mL). The reaction mixture was stirred in a preheated 90° C. oil bath for 16 h. The reaction mixture was diluted with water and EtOAc. The phases were mixed and the organic layer was separated. The aqueous phase was extracted with additional EtOAc and the combined organic phases were washed with brine, dried over MgSO4 and concentrated in vacuo. The crude residue was purified by silica gel chromatography (eluent: 20-100% EtOAc-EtOH (3:1) / heptane) to give tert-butyl (2R,5S,M)-4-(7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a yellow / orange solid (0.3 g, 0.484 mmol, 96% yield). 11H NMR (400 MHz, DMSO-d6) δ ppm 8.44 (d, J = 4.98 Hz, 1H) 8.27 (d, J = 9.54 Hz, 1H) 7.23 (d, J = 4.98 Hz, 1H) 7.07 - 7.14 (m, 1H) 6.49 (d, J = 8.29 Hz, 1H) 6.34 - 6.41 (m, 1H) 5.37 (s, 2H) 4.81 (br s, 1H) 4.25 - 4.44 (m, 1H) 4.13 (br d, J = 13.89 Hz, 1H) 3.77 - 3.86 (m, 1H) 3.72 (br d, J = 13.89 Hz, 1H) 3.48 - 3.64 (m, 1H) 2.66 - 2.79 (m, 1H) 1.94 (s, 3H) 1.46 (s, 8H) 1.43 - 1.49 (m, 1H) 1.34 (d, J = 6.43 Hz, 3H) 1.20 (br dd, J = 6.84, 2.90 Hz, 3H) 1.07 (d, J = 6.63 Hz, 3H) 0.96 (d, J = 6.63 Hz, 3H). 19 19F NMR (376 MHz, DMSO-d6) δ ppm -114.23 (br d, J = 28.61 Hz, 1F) -127.15 (br d, J = 28.61 Hz, 1F). m / z (ESI, pos): 620.3 (M + H) + .
[0240] Step 2: 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. To a solution of (2R,5S,M)-4-(7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-tert-butyl carboxylate (0.3 g, 0.484 mmol) in DCM (9.68 mL) was added trifluoroacetic acid (1.44 mL, 19.4 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo to give crude (M)-7-(2-amino-6-fluorophenyl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one, which was used without further purification.
[0241] To the crude (M)-7-(2-amino-6-fluorophenyl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was added DCM (10 mL). The solution was cooled to -20 °C. DIPEA (0.423 mL, 2.42 mmol) was added followed by dropwise addition of acryloyl chloride (1.1 M solution in DCM, 0.396 mL, 0.436 mmol). The reaction mixture was stirred for 5 min. The reaction mixture was concentrated in vacuo and purified by silica gel chromatography (eluent: 0-80% EtOAc-EtOH (3:1) / heptane). The resulting yellow solid was dissolved in EtOAc and washed successively with 1:1 saturated NaHCO3:water and brine, then dried over MgSO4 and concentrated in vacuo to give 4-((2S,5R,M)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (0.184 g, 0.321 mmol, 66.3% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 8.44(d,J=4.77Hz,1H)8.27-8.32(m,1H)7.21-7.24(m,1H)7.07-7.14(m,1H)6.78-6.92 (m,1H)6.48(d,J=8.29Hz,1H)6.34-6.41(m,1H)6.20(dd,J=16.59,2.28Hz,1H)5.73-5. 79(m,1H)5.37(s,2H)4.12-4.91(m,4H)3.47-3.89(m,2H)2.66-2.78(m,1H)1.94(s,3H) 1.33(t,J=6.53Hz,3H)1.18-1.29(m,3H)1.07(d,J=6.63Hz,3H)0.96(d,J=6.63Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -114.36--114.15(m,1F)-127.28--127.04(m,1F).m / z(ESI, positive):573.6(M+H) + .
[0242] Example 7 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0243] Step 1: 4,6-Diisopropylpyrimidin-5-amine. A solution of 4,6-dichloro-5-aminopyrimidine (3.00 g, 18.29 mmol, Combi-Blocks Inc., San Diego, CA) in THF (18 mL) was degassed by bubbling argon through the mixture for 5 min. 2-Propylzinc bromide (0.5 M solution in THF, 91.0 mL, 45.5 mmol, Sigma-Aldrich, St. Louis, MO) was added via syringe followed by XantPhos Pd G3 (434 mg, 0.46 mmol, Sigma-Aldrich, St. Louis, MO). The resulting mixture was stirred at room temperature for 16 h and then filtered through a pad of Celite. The filter cake was rinsed with EtOAc and the filtrate was collected and concentrated in vacuo to give 4,6-diisopropylpyrimidin-5-amine (3.45 g). This material was used in the subsequent step without further purification. m / z (ESI, positive ion): 180.2 (M+H)+.
[0244] Step 2: 2,5,6-trichloro-N-((4,6-diisopropylpyrimidin-5-yl)carbamoyl)nicotinamide. A solution of 2,5,6-trichloronicotinamide (Intermediate A, 3.30 g, 14.6 mmol) in 1,2-dichloroethane (49 mL) was treated with oxalyl chloride (2 M solution in DCM, 11.0 mL, 22.0 mmol). The mixture was heated at 80° C. for 45 min, then the heat was removed and the reaction was concentrated in vacuo. The residue was dissolved in acetonitrile (49 mL), cooled to −10° C., and a solution of 4,6-diisopropylpyrimidin-5-amine (3.15 g, 17.6 mmol) in acetonitrile (5 mL) was added via cannula. The resulting mixture was stirred at room temperature overnight and then concentrated in vacuo. The residue was suspended in warm 10:1 heptane / EtOAc (110 mL) and filtered. The filtrate was concentrated and the residue was purified by silica gel chromatography (eluent: 0-40% EtOAc / heptane) to give 2,5,6-trichloro-N-((4,6-diisopropylpyrimidin-5-yl)carbamoyl)nicotinamide. 1 H NMR(400MHz,DMSO-d6)δ ppm 11.30-11.46(m,1H),9.66(br s,1H),8.95-9.01(m,1H),8.65-8.72(m,1H),3.26(s,2H),1.17(d,J=6.6Hz,12H).m / z(ESI, cation):430.0(M+H) + .
[0245] Step 3: 6,7-Dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate J). To a -20°C solution of 2,5,6-trichloro-N-((4,6-diisopropylpyrimidin-5-yl)carbamoyl)nicotinamide (2.10 g, 4.9 mmol) in THF (49 mL) was added KHMDS (1 M solution in THF, 12.2 mL, 12.2 mmol). The ice bath was removed and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with saturated aqueous ammonium chloride (50 mL), diluted with brine, and extracted with 3:1 EtOAc / MeOH. The layers were separated and the aqueous layer was extracted with additional EtOAc. The combined organic layers were dried over anhydrous MgSO4 and concentrated in vacuo. The residue was suspended in heptane / EtOAc and filtered. The filtrate was concentrated to give 6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione. 1 H NMR(400MHz,DMSO-d6)δ ppm 12.33(s,1H),9.18(s,1H),8.61(s,1H),2.90-3.02(m,2H),1.10(d,J=6.6Hz,6H),0.99(d,J=6.6Hz,6H).m / z(ESI, cation):394.1(M+H) + .
[0246] Step 4: (2R,5S)-tert-butyl 4-(6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (Intermediate K). A 150 mL round-bottom flask was charged with 6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate J, 0.400 g, 1.01 mmol) and N,N'-diisopropylethylamine (0.230 mL, 1.32 mmol) in acetonitrile (5.07 mL). Phosphite oxychloride (0.113 mL, 1.22 mmol) was then added slowly to the reaction mixture. The mixture was stirred and heated at 80° C. while the flask was fitted with an air-cooled condenser and subsequently placed under an inert (N2) atmosphere for 30 minutes. At this point the reaction was stopped and the mixture was removed from the heat bath and allowed to cool to room temperature. The reaction mixture was cooled to 0° C. DIPEA (0.5 mL) was slowly added to the mixture. A mixture of (2R,5S)-1-Boc-2,5-dimethylpiperazine (0.435 g, 2.03 mmol) in acetonitrile (5 mL) was then slowly added to the reaction mixture. The ice bath was removed and the entire mixture was allowed to slowly warm to room temperature over 10 minutes. The reaction mixture was concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-50% EtOAc / heptane) to give (2R,5S)-tert-butyl-4-(6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a pale yellow solid (0.402 g, 0.681 mmol, 67.1% yield). m / z (ESI, positive ion): 590.2 (M+H). + .
[0247] Step 5: (2R,5S)-tert-butyl 4-(6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate. To a 100 mL round bottom flask was added (2R,5S)-tert-butyl 4-(6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (Intermediate K, 0.250 g, 0.423 mmol) in 1,4-dioxane (2.12 mL) and KOAc (0.125 g, 1.27 mmol). The reaction mixture was degassed by bubbling N2 through the mixture for 5 min. Then, (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.031 g, 0.042 mmol) was added to the reaction mixture, followed by 2-fluorophenylboronic acid (0.118 g, 0.847 mmol) and water (0.3 mL). The mixture was stirred and heated at 90 °C for 15 min. The reaction mixture was diluted with saturated aqueous ammonium chloride and EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic extracts were dried over Mg2SO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-100% EtOAc / heptane) to give (2R,5S)-tert-butyl-4-(6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a pale yellow solid (0.245 g, 0.377 mmol, 89% yield). m / z (ESI, positive ion): 650.3 (M+H). + .
[0248] Step 6: 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. To a 100 mL round bottom flask was added tert-butyl (2R,5S)-4-(6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (0.235 g, 0.361 mmol) in DCM (3.61 mL) and trifluoroacetic acid (0.269 mL, 3.61 mmol). The reaction mixture was stirred and heated under an inert (N2) atmosphere for 2.5 hours at 38° C. The reaction mixture was concentrated in vacuo to give crude 6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one, which was taken directly into the next step of the synthesis without further purification.
[0249] 6-Chloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one was dissolved in dichloromethane (3.61 mL) and the mixture was cooled to 0° C. DIPEA (0.758 mL, 4.34 mmol) was added to the reaction mixture and the mixture was stirred for 2 min. Acryloyl chloride (0.029 mL, 0.361 mmol) was added dropwise to the mixture. The mixture was diluted with EtOAc and saturated aqueous NaHCO3 and the layers were separated. The aqueous layer was extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-5% MeOH / DCM) to give 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a white solid (0.110 g, 0.182 mmol, 50.4% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 9.07(s,1H)8.50(d,J=4.98Hz,1H)7.49-7.56(m,1H)7.26-7.35(m,2H)7.20(t,J=6.91Hz,1H)6.78-6.91(m,1H)6.20(br d,J=17.21Hz,1H)5.73-5.79(m,1H)4.89(br s,1H)4.79(br s,1H)4.14-4.28(m,1H)4.08(br d,J=5.18Hz,1H)3.88(br t,J=13.58Hz,2H)3.16-3.28(m,2H)2.66-2.80(m,2H)1.32-1.39(m,3H)1.19-1.22(m,1H)1.09(dd,J=6.63,2.70Hz,6H)0.95(br d,J=6.43Hz,6H).m / z(ESI, cation):604.4(M+H) + .
[0250] Example 8 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0251] Step 1: Potassium (2-fluoro-6-hydroxyphenyl) trifluoroborate (Intermediate L). A solution of potassium fluoride (44.7 g, 770 mmol) in water (75 mL) was added to a suspension of (2-fluoro-6-hydroxyphenyl)boronic acid (30 g, 192 mmol, Combi-Blocks, San Diego, CA) in acetonitrile (750 mL). The mixture was stirred for 2 minutes, followed by the addition of a solution of L-(+)-tartaric acid (72.2 g, 481 mmol) in THF (375 mL) via addition funnel over 10 minutes. The mixture was stirred vigorously with a mechanical stirrer for 1 hour, the resulting suspension was filtered, and the filtered solid was washed with a small amount of THF. The solid was discarded and the filtrate was partially concentrated until solids began to precipitate out of solution. The mixture was then cooled to -20°C and stirred for 16 hours. The reaction was allowed to warm slowly and 2-propanol (20 mL) was added. The resulting suspension was filtered and the filtered solid was washed with 2-propanol. The filtrate was partially concentrated again until a suspension was formed, then cooled to -20°C and stirred for an additional 20 minutes. The resulting suspension was diluted with 2-propanol, filtered and the filtered solid was washed with 2-propanol. The two batches of solid were combined to give potassium (2-fluoro-6-hydroxyphenyl) trifluoroborate. 1 H NMR(400MHz,DMSO-d6)δ ppm 8.07(q,J=14.7Hz,1H)6.93(q,J=7.5Hz,1H)6.30-6.38(m,2H).
[0252] Step 2: 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate M). To a 100 mL round bottom flask was added (2R,5S)-4-(6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate tert-butyl (Intermediate K, 0.479 g, 0.811 mmol) in 1,2-dichloroethane (4.06 mL) and trifluoroacetic acid (1.21 mL, 16.2 mmol). The reaction mixture was stirred and heated under an inert (N2) atmosphere for 1 h at 70° C. The reaction mixture was concentrated in vacuo to give crude 6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one, which was taken directly into the next step of the synthesis without further purification.
[0253] 6,7-Dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was diluted with DCM (4 mL) and the reaction mixture was then cooled to 0° C. DIPEA (1.70 mL, 9.73 mmol) was added to the reaction mixture and the mixture was stirred for 2 min. Acryloyl chloride (0.066 mL, 0.811 mmol) was added dropwise to the reaction mixture. The mixture was diluted with DCM and saturated aqueous NaHCO3 and the layers were then separated. The aqueous layer was extracted with DCM. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-100% EtOAc / heptane followed by a gradient of 0-5% MeOH / DCM) to give 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a tan solid (0.397 g, 0.729 mmol, 90% yield). m / z (ESI, positive ion): 544.1 (M+H). + .
[0254] Step 3: 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. A 100 mL round-bottom flask was charged with 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate M, 0.152 g, 0.279 mmol) and KOAc (0.082 g, 0.837 mmol) in 1,4-dioxane (1.40 mL). The reaction mixture was degassed by bubbling argon through the mixture for 5 minutes. Then, (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.020 g, 0.028 mmol) was added to the mixture. The mixture was stirred and heated at 90° C. for 10 minutes. Then, a mixture of potassium trifluoro(2-fluoro-6-hydroxyphenyl)borate (Intermediate L, 0.183 g, 0.837 mmol) in 1,4-dioxane (1 mL) was slowly added to the reaction mixture, followed by water (0.8 mL). The reaction mixture was stirred and heated at 90° C. for 1 hour. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-5% MeOH / DCM) to give 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a pale yellow solid (0.115 g, 0.185 mmol, 66.4% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 10.12(br d,J=13.27Hz,1H)9.05(s,1H)8.48(br s,1H)7.20-7.28(m,1H)6.84(td,J=17.52,10.57Hz,1H)6.64-6.75(m,2H)6.20(dd,J=16.69,2.18Hz,1H)5.73-5.80(m,1H)4.75 -4.98(m,2H)4.14-4.30(m,1H)3.80-3.95(m,2H)3.39-3.54(m,1H)2.56-2.78(m,2H)1.19-1.39(m,6H)1.03-1.15(m,6H)0.95(br s,6H).m / z(ESI,cation):620.0(M+H) + .
[0255] Example 9 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0256] 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A 100 mL round-bottom flask was charged with 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate M, 0.230 g, 0.422 mmol) in 1,4-dioxane (2.11 mL) and KOAc (0.124 g, 1.27 mmol). The reaction mixture was degassed by bubbling argon through the mixture for 5 minutes. Then, (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.031 g, 0.042 mmol) was added to the mixture. The mixture was stirred and heated at 90° C. for 10 minutes. Then, a mixture of (2-amino-6-fluorophenyl)boronic acid pinacol ester (0.200 g, 0.845 mmol, CombiPhos, Trenton, NJ) in 1,4-dioxane (1 mL) was slowly added to the reaction mixture, followed by 6 drops of water. The entire reaction mixture was stirred and heated at 90° C. for 1 hour. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-5% MeOH / DCM) to give 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a yellow solid (0.155 g, 0.250 mmol, 59.3% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 9.05(s,1H)8.45-8.49(m,1H)7.00-7.09(m,1H)6.78-6.91(m,1H)6.44(d,J=8.29Hz ,1H)6.31(q,J=9.12Hz,1H)6.19(dd,J=16.59,2.07Hz,1H)5.72-5.79(m,1H)5.11(br d,J=11.40Hz,2H)4.72-4.95(m,2H)4.09-4.24(m,1H)3.82-4.01(m,2H)3.44-3.61(m,1H)2.78-2.94( m,1H)2.53-2.68(m,1H)1.17-1.37(m,6H)1.07(s,6H)0.87-1.03(m,6H).m / z(ESI, cation):619.2(M+H) + .
[0257] Example 10 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0258] Step 1: 2,6-dichloro-N-((4,6-diisopropylpyrimidin-5-yl)carbamoyl)-5-fluoronicotinamide. A 250 mL round bottom flask was charged with 2,6-dichloro-5-fluoronicotinamide (Intermediate F, 4.45 g, 21.3 mmol) and oxalyl chloride (16.0 mL, 31.9 mmol) in THF (71.0 mL). The flask was fitted with an air-cooled condenser and the mixture was stirred and heated at 80° C. for 1 h. The reaction mixture was concentrated in vacuo to give (2,6-dichloro-5-fluoronicotinoyl)carbamic chloride, which was taken on to the next step of the synthesis without further purification.
[0259] A 250 mL round bottom flask was charged with (2,6-dichloro-5-fluoronicotinoyl)carbamoyl isocyanate (crude material from previous step) in tetrahydrofuran (71.0 mL). A solution of 4,6-diisopropylpyrimidin-5-amine (4.01 g, 22.4 mmol) in THF (10 mL) was then added dropwise to the reaction mixture. The mixture was stirred at room temperature for 1.5 h under an inert (N2) atmosphere. The reaction mixture was concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-40% EtOAc / heptane) to give 2,6-dichloro-N-((4,6-diisopropylpyrimidin-5-yl)carbamoyl)-5-fluoronicotinamide (7.74 g, 18.7 mmol, 88% yield) as a pale yellow solid. 1 H NMR(400MHz,DMSO-d6)δ ppm 11.41(br s,1H)9.66(br s,1H)8.99(s,1H)8.54(br d,J=7.88Hz,1H)3.20-3.28(m,2H)1.17(d,J=6.84Hz,12H).m / z(ESI, cation):414.0(M+H) + .
[0260] Step 2: 7-Chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate N). A 250 mL round bottom flask was charged with 2,6-dichloro-N-((4,6-diisopropylpyrimidin-5-yl)carbamoyl)-5-fluoronicotinamide (4.00 g, 9.66 mmol) in THF (48.3 mL). The reaction mixture was cooled to 0° C. in a wet ice / water bath. Potassium bis(trimethylsilyl)amide, 1 M solution in THF (12.1 mL, 12.1 mmol) was then added dropwise to the reaction mixture via addition funnel over 5 min. The ice bath was removed and the reaction mixture was allowed to slowly warm to room temperature with stirring under an inert (N2) atmosphere for 1 h. Additional KHMDS (0.5 equiv; 6 mL) was added dropwise to the reaction mixture until most of the starting material was consumed. The reaction mixture was quenched with saturated aqueous ammonium chloride (50 mL), and the mixture was subsequently diluted with EtOAc-MeOH (3:1) and brine solution. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo to give 7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.58 g, 6.84 mmol, 70.9% yield) as a tan solid. 1 H NMR(400MHz,DMSO-d6)δ ppm 12.03-12.52(m,1H)8.97-9.23(m,1H)8.25-8.58(m,1H)2.80(dt,J=13.22,6.56H z,2H)0.96(d,J=6.63Hz,6H)0.85(d,J=6.63Hz,6H).m / z(ESI, cation):378.0(M+H) + .
[0261] Step 3: 4-(7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (2R,5S)-tert-butyl (Intermediate O). 7-Chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2,4(1H,3H)-dione (Intermediate N, 0.300 g, 0.794 mmol) and DIPEA (0.180 mL, 1.03 mmol) in acetonitrile (7.94 mL) were added to a 100 mL round-bottom flask. Phosphorous acid oxychloride (0.089 mL, 0.953 mmol) was then added slowly to the reaction mixture. The mixture was stirred and heated at 80° C. while the flask was fitted with an air-cooled condenser and placed under an inert (N2) atmosphere for 45 min. The reaction mixture was removed from the heat bath and allowed to cool to room temperature. The reaction mixture was cooled to 0° C. DIPEA (0.5 mL) was then added slowly to the reaction mixture. A mixture of (2R,5S)-1-Boc-2,5-dimethylpiperazine (0.213 g, 0.993 mmol) in acetonitrile (1 mL) was then added slowly to the reaction mixture. The ice bath was removed and the entire mixture was allowed to warm slowly to room temperature over 1 h. The mixture was diluted with EtOAc and the layers were separated. The aqueous layer was extracted with EtOAc and brine. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-100% EtOAc / heptane) to give tert-butyl (2R,5S)-4-(7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a tan solid (0.247 g, 0.430 mmol, 54.2% yield). 11H NMR (400 MHz, DMSO-d6) δ ppm 9.15 (s, 1H) 8.39 (d, J = 8.29 Hz, 1H) 5.14 (t, J = 5.81 Hz, 1H) 4.49 (d, J = 5.80 Hz, 3H) 4.06 (br d, J = 13.89 Hz, 1H) 3.66 (br s, 1H) 2.66 - 2.72 (m, 2H) 1.44 (s, 9H) 1.31 (d, J = 6.63 Hz, 3H) 1.10 - 1.14 (m, 3H) 1.09 (s, 6H) 0.98 - 1.04 (m, 6H). m / z (ESI, positive ion): 574.2 (M + H) + .
[0262] Step 4: (2R,5S)-tert-butyl 4-(1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate. A 100 mL round-bottom flask was charged with (2R,5S)-4-(7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate tert-butyl (Intermediate O, 0.225 g, 0.392 mmol) and KOAc (0.115 g, 1.18 mmol) in 1,4-dioxane (2.54 mL). The reaction mixture was degassed by bubbling N2 through the mixture for 5 min. Then, (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.029 g, 0.039 mmol) was added to the reaction mixture, followed by 2-fluorophenylboronic acid (0.066 g, 0.470 mmol) and water (0.1 mL). The mixture was stirred and heated at 80°C for 45 min. The reaction mixture was diluted with saturated aqueous ammonium chloride and EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-100% EtOAc / heptane) to give tert-butyl (2R,5S)-4-(1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate as a tan solid (0.225 g, 0.355 mmol, 91% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 9.09(s,1H)8.34(d,J=9.54Hz,1H)7.55(br d,J=7.46Hz,1H)7.22-7.25(m,3H)4.85(br s,1H)4.27-4.40(m,1H)4.16(br d,J=14.10Hz,1H)3.71(br d,J=13.48Hz,2H)3.46-3.61(m,1H)2.68-2.77(m,2H)1.45(s,9H)1.34(d,J=6.63Hz,3H)1.18(br d,J=6.22Hz,3H)1.09(s,6H)0.94(d,J=6.63Hz,6H).m / z(ESI, cation):634.4(M+H) + .
[0263] Step 5: 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. To a 100 mL round bottom flask was added tert-butyl (2R,5S)-4-(1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (0.225 g, 0.355 mmol) in DCM (3.37 mL) and trifluoroacetic acid (0.265 mL, 3.55 mmol). The reaction mixture was stirred and heated at 38° C. for 2.5 hours under an inert (N2) atmosphere. The reaction mixture was concentrated in vacuo to give 1-(4,6-diisopropylpyrimidin-5-yl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. This material was taken directly into the next step of the synthesis without further purification.
[0264] The crude 1-(4,6-diisopropylpyrimidin-5-yl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one was diluted with dichloromethane (3.37 mL) and cooled to 0° C. Then, N,N′-diisopropylethylamine (0.744 mL, 4.26 mmol) was added to the reaction mixture and the mixture was stirred for 2 min. Acryloyl chloride (0.029 mL, 0.355 mmol) was added dropwise to the reaction mixture which was stirred for 30 min under an inert (N2) atmosphere. The mixture was diluted with DCM and saturated aqueous NaHCO3, then the layers were separated. The aqueous layer was extracted with DCM. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-5% MeOH / DCM) to give 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a tan solid (0.070 g, 0.119 mmol, 33.5% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 9.03(s,1H)8.30(dd,J=9.43,4.87Hz,1H)7.48(q,J=6.98Hz,1H)7.16-7.30(m,3H)6.71-6.84(m,1H)6.12(br d,J=17.00Hz,1H)5.69(br d,J=10.16Hz,1H)4.67-4.89(m,2H)4.06-4.19(m,1H)3.74-3.85(m,2H)2.65(dq,J=12.75,6.39Hz,2H)1.27(t,J=5.91Hz,3H)1.19(br d,J=6.63Hz,2H)1.12(d,J=6.63Hz,2H)1.02(dd,J=6.63,1.87Hz,6H)0.87(d,J=6.63Hz,6H).m / z(ESI, cation):588.2(M+H) + .
[0265] Example 11 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0266] Step 1: 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate P). To a 100 mL round bottom flask was added (2R,5S)-4-(7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate tert-butyl (Intermediate O, 0.590 g, 1.03 mmol) in DCM (3.37 mL) and trifluoroacetic acid (1.53 mL, 20.5 mmol). The reaction mixture was stirred and heated at 38° C. for 16 h under an inert (N2) atmosphere. The reaction mixture was concentrated in vacuo to give 7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one. This material was taken directly into the next step of the synthesis without further purification.
[0267] The crude 7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one was diluted with DCM (3.37 mL) and the reaction mixture was cooled to 0° C. DIPEA (2.15 mL, 12.3 mmol) was added to the reaction mixture and the mixture was stirred for 2 min. Acryloyl chloride (0.084 mL, 1.03 mmol) was added dropwise to the reaction mixture. The mixture was diluted with DCM and saturated aqueous NaHCO3 and the layers were separated. The aqueous layer was extracted with DCM. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-100% EtOAc / heptane followed by a gradient of 0-5% MeOH / DCM) to give 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one as a tan solid (0.472 g, 0.894 mmol, 87% yield). m / z (ESI, positive ion): 528.1 (M+H). + .
[0268] Step 2: 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. A 100 mL round-bottom flask was charged with 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate P, 0.210 g, 0.398 mmol) and KOAc (0.117 g, 1.19 mmol) in 1,4-dioxane (2.0 mL). The reaction mixture was degassed by bubbling argon through the mixture for 5 minutes. (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.029 g, 0.040 mmol) was added to the mixture. The mixture was stirred and heated at 90° C. for 10 minutes. Potassium trifluoro(2-fluoro-6-hydroxyphenyl)borate (Intermediate L, 0.173 g, 0.795 mmol) in 1,4-dioxane (1 mL) was then added slowly to the reaction mixture, followed by water (0.8 mL). The reaction mixture was stirred and heated at 90° C. for 1 hour. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-5% MeOH / DCM) to give 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a pale yellow solid (0.180 g, 0.298 mmol, 75.0% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 10.20(s,1H)9.05(s,1H)8.32(dd,J=8.91,4.15Hz,1H)7.22-7.30(m,1H)6.65-6.90(m,3H)6 .18(dd,J=16.59,2.07Hz,1H)5.72-5.78(m,1H)4.73-4.96(m,2H)4.13-4.22(m,1H)3.85(br s,2H)3.41-3.56(m,1H)2.62-2.74(m,2H)1.19-1.36(m,6H)1.08(dd,J=6.63,1.45Hz,6H)0.93(br d,J=5.39Hz,6H).m / z(ESI, cation):604.1(M+H) + .
[0269] Example 12 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0270] 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one. A 100 mL round-bottom flask was charged with 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate P, 0.250 g, 0.473 mmol) and KOAc (0.139 g, 1.420 mmol) in 1,4-dioxane (2.37 mL). The reaction mixture was degassed by bubbling argon through the mixture for 5 minutes. Then, (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.035 g, 0.047 mmol) was added to the mixture. The mixture was stirred and heated at 90° C. for 10 minutes. Then, a mixture of (2-amino-6-fluorophenyl)boronic acid pinacol ester (0.224 g, 0.947 mmol, CombiPhos, Trenton, NJ) in 1,4-dioxane (1 mL) was slowly added to the reaction mixture, followed by 6 drops of water. The entire reaction mixture was stirred and heated at 90° C. for 1 hour. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-5% MeOH / DCM) to give 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one as a yellow solid (0.138 g, 0.229 mmol, 48.4% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 9.09(s,1H)8.35(br d,J=9.33Hz,1H)7.07-7.14(m,1H)6.78-6.92(m,1H)6.48(d,J=8.47Hz,1H)6. 36(t,J=9.12Hz,1H)6.20(dd,J=16.69,2.18Hz,1H)5.73-5.80(m,1H)5.31(s, 2H)4.76-4.94(m,2H)4.15-4.22(m,1H)3.82-3.91(m,2H)3.45-3.57(m,1H)2. 67-2.79(m,2H)1.30-1.37(m,3H)1.18-1.29(m,3H)1.05-1.09(m,6H)0.95(br d,J=6.63Hz,6H).m / z(ESI,cation):603.2(M+H) + .
[0271] Example 13 (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0272] Step 1: (M)-4-(6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate tert-butyl. A solution of (M)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2,4(1H,3H)-dione (Intermediate D, 0.143 g, 0.337 mmol), phosphoryl trichloride (0.038 mL, 0.40 mmol) and DIPEA (0.176 mL, 1.01 mmol) in acetonitrile (0.8 mL) was stirred at 80° C. for 30 min. The reaction mixture was removed from the heat block and tert-butyl cis-2,6-dimethylpiperazine-1-carboxylate (0.072 g, 0.337 mmol; Enamine, Monmouth Jct., NJ) and DIPEA (0.176 mL, 1.01 mmol) were added. The reaction mixture was stirred at room temperature for 15 min. The reaction mixture was diluted with EtOAc (100 mL), added to a separatory funnel and washed with saturated aqueous NaHCO3 (2 x 75 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product was adsorbed onto silica and purified by silica gel chromatography (eluent: 0-70% EtOAc / EtOH (3:1) / heptane) to give (M)-tert-butyl 4-(6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate as an amber oil. 1H NMR(400MHz,CDCl3)δ 8.45-8.52(m,1H)8.34(s,1H)7.41(br d,J=6.6Hz,1H)7.04-7.20(m,4H)4.45(br s,2H)4.31(br d,J=13.3Hz,2H)3.54(br d,J=13.3Hz,2H)2.74(dt,J=13.1,6.5Hz,1H)2.04(s,3H)1.53(s,9H)1.25-1.32(m,6H)1.23(br d,J=6.8Hz,3H)1.06(br d,J=6.6Hz,3H). 19 F NMR(377MHz,CDCl3)δ -112.61(s,1F).m / z(ESI, cation):621.0(M+H) + .
[0273] Step 2: (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A solution of (M)-4-(6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate tert-butyl (0.209 g, 0.336 mmol) in trifluoroacetic acid (2.6 mL, 34 mmol) was stirred at room temperature for 15 minutes. The reaction mixture was concentrated in vacuo to give crude (M)-6-chloro-4-(cis-3,5-dimethylpiperazin-1-yl)-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as an oil.
[0274] A solution of crude (M)-6-chloro-4-(cis-3,5-dimethylpiperazin-1-yl)-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one, DIPEA (0.176 mL, 1.01 mmol) and acryloyl chloride (0.5 M in DCM, 0.673 mL, 0.336 mmol) in DCM (1.7 mL) was stirred at room temperature for 15 min. The reaction mixture was diluted with EtOAc (100 mL), added to a separatory funnel and washed with saturated aqueous NaHCO3 (2 x 75 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product was adsorbed onto silica and purified by silica gel chromatography (eluent: 0-100% EtOAc / EtOH (3:1) / heptane) to give (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a pale yellow waxy solid (85 mg, 0.15 mmol, 44% yield). 1 H NMR(400MHz,CDCl3)δ 8.49(br s,1H)8.33(br s,1H)7.42(br d,J=3.3Hz,1H)7.03-7.21(m,4H)6.58-6.72(m,1H)6.44(br d,J=15.8Hz,1H)5.81(br d,J=9.1Hz,1H)4.73(br s,2H)4.35(br d,J=13.1Hz,2H)3.62(br d,J=11.8Hz,2H)2.64-2.79(m,1H)2.04(br s,3H)1.58(br s,6H)1.19-1.25(m,3H)1.02-1.09(m,3H). 19 F NMR(377MHz,CDCl3)δ -112.58(s,1F).m / z(ESI, cation):574.8(M+H) + .
[0275] Example 14 (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0276] Step 1: (M)-tert-Butyl 4-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate. Phosphorous acid oxychloride (0.37 mL, 3.92 mmol) was added dropwise to a solution of (M)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (1.17 g, 3.20 mmol, intermediate C) and DIPEA (0.74 mL, 4.25 mmol) in acetonitrile (3.27 mL). The mixture was heated to 80° C. for 1 h and then cooled to 0° C. DIPEA (1.71 mL, 9.80 mmol) and t-butyl cis-2,6-dimethylpiperazine-1-carboxylate (0.70 g, 3.27 mmol, Enamine, San Diego, Calif.) were added. The mixture was allowed to warm to room temperature and stirred for 1 h, then poured into a cold solution of saturated NaHCO3 and stirred vigorously for 10 min. The mixture was partitioned between EtOAc and brine, the layers were separated, the aqueous layer was back-extracted with EtOAc, and the combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography (eluent: 0-40% EtOAc-EtOH (3:1) / heptane) to give (M)-tert-butyl 4-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate as a white solid (1.65 g, 2.94 mmol, 90% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 8.58-8.47(m,2H),7.26(m,1H),4.23(m,4H),3.58(m,2H),2.66-2.61(m,1H),1.94(s ,3H),1.44(s,9H),1.32-1.27(m,6H),1.08-0.97(m,6H).m / z(ESI, cation):561.0(M+H) + .
[0277] Step 2: (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate Q). A vial was charged with (M)-4-(6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-tert-butyl carboxylate (1.65 g, 2.94 mmol), dichloromethane (14.7 mL) and trifluoroacetic acid (4.4 mL, 58.8 mmol). The mixture was stirred at room temperature for 1 h, partitioned between EtOAc / NaHCO3, washed with NaHCO3, washed with brine, dried over MgSO4 and concentrated in vacuo to give crude (M)-6,7-dichloro-4-(cis-3,5-dimethylpiperazin-1-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one.
[0278] The residue of (M)-6,7-dichloro-4-(cis-3,5-dimethylpiperazin-1-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was redissolved in DCM (14.7 mL) followed by the dropwise addition of acryloyl chloride (2.80 mL, 3.09 mmol). The reaction was stirred at room temperature for 30 min, partitioned between EtOAc and saturated NaHCO3, washed with saturated NaHCO3, washed with brine, dried over MgSO4, and purified by silica gel chromatography (eluent: 30-100% tOAc-EtOH (3:1) / heptane) to give (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a white solid (1.18 g, 78% yield), which was used without further purification. m / z (ESI, cation): 515.0 (M+H). + .
[0279] Step 3: (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate Q, 0.30 g, 0.57 mmol), potassium trifluoro(2-fluoro-6-hydroxyphenyl)borate (0.15 g, 0.69 mmol, Intermediate L), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.04 g, 0.06 mmol) and KOAc (0.28 g, 2.86 mmol). The flask was evacuated and backfilled with N2, after which 1,4-dioxane (2.30 mL) and water (0.57 mL) were added. The mixture was stirred at 90 °C for 18 h and purified by silica gel chromatography (eluent 30-100% EtOAc-EtOH (3:1) / heptane) to give 0.26 g of crude material, which was further purified using preparative SFC (eluent 20% MeOH) to give (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a yellow solid (0.12 g, 34.3% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 10.13(br s,1H),8.51(s,1H),8.38(d,J=5.0Hz,1H),7.27-7.14(m,2H),6.81(dd,J=10.6,16.6 Hz,1H),6.74-6.62(m,2H),6.20(dd,J=2.4,16.7Hz,1H),5.79-5.71(m,1H),4.58(br s,2H),4.32(br t,J=15.7Hz,2H),3.63(m,2H),2.76-2.68(m,1H),1.91(m,3H),1.41(m,6H),1.07(d,J=6.8Hz,3H),0.92(br d,J=6.6Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -113.91(s,1F).m / z(ESI, cation):591.0(M+H) + .
[0280] Example 15 (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0281] (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate Q, 0.30 g, 0.57 mmol), (2-amino-6-fluorophenyl)boronic acid pinacol ester (0.15 g, 0.63 mmol, CombiPhos, Trenton, NJ), tetrakis(triphenylphosphine)palladium(0) (0.07 g, 0.06 mmol) and KOAc (0.28 g, 2.86 mmol). The flask was evacuated and backfilled with N2, after which 1,4-dioxane (2.30 mL) and water (0.57 mL) were added. The mixture was stirred at 90° C. for 18 h and purified by silica gel chromatography (eluent: 30-100% EtOAc-EtOH (3:1) / heptane) to give crude material which was further purified using preparative SFC (eluent 15% MeOH) to give (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a yellow solid (0.17 g, 49% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 8.50(s,1H),8.39(d,J=5.0Hz,1H),7.19(d,J=4.8Hz,1H),7.09-7.02(m,1H),6.81(dd,J=10.5,16.5Hz,1H),6.44(m 1H),6.31(t,J=8.9Hz,1H),6.20(dd,J=2.2,16.5Hz,1H),5.77-5.73(m,1H),5.11(br s,2H),4.60(m,2H),4.37-4.24(m,2H),3.64(m,2H),2.91-2.68(m,1H),1.99(s,3H),1.39-1.41(m 6H),1.11-1.02(m,3H),0.88(d,J=6.6Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -115.73(s,1F).m / z(ESI, cation):591.0(M+H) + .
[0282] Example 16 (M)-4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0283] Step 1: (M)-tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate. Phosphorous acid oxychloride (0.34 mL, 3.63 mmol) was added dropwise to a solution of (M)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate G, 1.03 g, 2.96 mmol) and Hunig's base (0.69 mL, 3.93 mmol) in acetonitrile (3.02 mL). The mixture was heated to 80° C. for 1 h and then cooled to 0° C. DIPEA (1.58 mL, 9.07 mmol) and t-butyl cis-2,6-dimethylpiperazine-1-carboxylate (0.64 g, 3.62 mmol, Enamine, San Diego, Calif.) were added. The mixture was allowed to warm to room temperature and stirred for 1 h, then poured into a cold solution of saturated NaHCO3 and stirred vigorously for 10 min. The mixture was partitioned between EtOAc and brine, the layers were separated, the aqueous layer was back-extracted with EtOAc, and the combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography (eluent: 0-40% EtOAc-EtOH (3:1) / heptane) to give (M)-tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate as a white solid (1.38 g, 84% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 8.48(d,J=4.8Hz,1H),8.40(d,J=8.5Hz,1H),7.26(d,J=4.8Hz,1H),4.32-4.16(m,4H),3.66-3.55( m,2H),2.65-2.56(m,1H),1.94(s,3H),1.44(s,9H),1.29(dd,J=3.1,6.6Hz,6H),1.14-0.95(m,6H). 19F NMR(376MHz,DMSO-d6)δ ppm -128.10(s,1F); m / z(ESI, cation):545.2(M+H) + .
[0284] Step 2: (M)-4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate R). A vial was charged with (M)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-tert-butyl carboxylate (1.38 g, 2.53 mmol), DCM (12.7 mL) and trifluoroacetic acid (3.77 mL, 50.6 mmol). The mixture was stirred at room temperature for 1 h, partitioned between EtOAc and NaHCO3, washed with NaHCO3, washed with brine, dried over MgSO4 and concentrated in vacuo to give (M)-7-chloro-4-(cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a crude residue.
[0285] The residue of (M)-7-chloro-4-(cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was redissolved in dichloromethane (12.7 mL) and acryloyl chloride (2.42 mL, 2.66 mmol) was added dropwise. The reaction was stirred at room temperature for 30 min, partitioned between EtOAc / NaHCO3, washed with NaHCO3, washed with brine, dried over MgSO4, and purified by silica gel chromatography (eluent: 30-100% EtOAc-EtOH (3:1) / heptane) to give (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a white solid (0.88 g, 1.77 mmol, 70.0% yield), which was used without further purification. m / z (ESI, cation): 499.0 (M+H). + .
[0286] Step 3: (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate R, 0.30 g, 0.59 mmol), (2-fluorophenyl)boronic acid (0.10 g, 0.71 mmol), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.04 g, 0.06 mmol) and KOAc (0.29 g, 2.96 mmol). The flask was evacuated and backfilled with N2, after which 1,4-dioxane (2.37 mL) and water (0.59 mL) were added. The mixture was stirred at 90° C. for 2 h, then cooled to room temperature and purified by silica gel chromatography (eluent: 30-100% EtOAc-EtOH (3:1) / heptane) to give (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as an orange solid (0.20 g, 63% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 8.43(d,J=5.0Hz,1H),8.39(d,J=9.7Hz,1H),7.60-7.45(m,1H),7.37-7.21(m,4H),6. 80(dd,J=10.6,16.6Hz,1H),6.19(dd,J=2.4,16.7Hz,1H),5.77-5.73(m,1H),4.57(br s,2H),4.33(m,2H),3.73-3.65(m,2H),2.75-2.68(m,1H),1.97-1.90(m, 3H),1.39(t,J=6.5Hz,6H),1.07(d,J=6.6Hz,3H),0.95(d,J=6.8Hz,3H). 19F NMR(376MHz,DMSO-d6)δ ppm -113.83(d,J=32Hz,1F),-128.96(d,J=32Hz,1F).m / z(ESI, cation):559.0(M+H) + .
[0287] Example 17 (M)-4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0288] (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate R, 0.30 g, 0.59 mmol), potassium trifluoro(2-fluoro-6-hydroxyphenyl)borate (0.15 g, 0.69 mmol, Intermediate L), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.04 g, 0.06 mmol) and KOAc (0.28 g, 2.86 mmol). The flask was evacuated and backfilled with N2, after which 1,4-dioxane (2.30 mL) and water (0.57 mL) were added. The mixture was stirred at 90 °C for 18 h and purified by silica gel chromatography (eluent: 30-100% EtOAc-EtOH (3:1) / heptane) to give (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as an orange solid (0.21 g, 0.37 mmol). 1H NMR(400MHz,DMSO-d6)δ ppm 10.20(br s,1H),8.39(d,J=5.0Hz,1H),8.33(d,J=9.1Hz,1H),7.31-7.23(m,1H),7.19(d,J=4. 8Hz,1H),6.84-6.66(m,3H),6.19(dd,J=2.5,16.6Hz,1H),5.77-5.73(m,1H),4.56(br s,2H),4.42-4.21(m,2H),3.66(ddd,J=3.8,4.0,13.3Hz,2H),2.74-2.68(m,1H) ,1.99-1.88(m,3H),1.41-1.39(m,6H),1.09-1.03(m,3H),0.92(d,J=6.6Hz,3H). 19 F NMR(377MHz,DMSO-d6)δ ppm -115.68(s,1F),-128.36(s,1F).m / z(ESI, cation):575.2(M+H) + .
[0289] Example 18 (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0290] (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate R, 0.3 g, 0.59 mmol), potassium carbonate (178 mg, 2.96 mmol), (2-amino-6-fluorophenyl)boronic acid pinacol ester (0.15 g, 0.65 mmol, CombiPhos, Trenton, NJ), tetrakis(triphenylphosphine)palladium(0) (68 mg, 0.06 mmol) and 1,4-dioxane (2.0 mmol). The mixture was degassed with N2, water (1.0 mL) was added, and the mixture was stirred at 90 °C for 2 h, then cooled to room temperature, adsorbed directly onto SiO2, and purified by silica gel chromatography (eluent: 30-100% EtOAc-EtOH (3:1) / heptane) to give (M)-4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as an orange solid (0.30 g, 88% yield). 1H NMR(400MHz,DMSO-d6)δ ppm 8.44(d,J=4.8Hz,1H),8.34(d,J=9.5Hz,1H),7.22(d,J=4.8Hz,1H),7.14-7.07(m,1H),6.81(dd,J=10.4,16.6 Hz,1H),6.48(d,J=8.3Hz,1H),6.37(t,J=8.8Hz,1H),6.19(dd,J=2.4,16.7Hz,1H),5.78-5.72(m,1H),4.57(br s,2H),4.33(m,2H),4.27(m,2H),3.73-3.64(m,2H),2.77-2.68(m,1H),1.99-1.90(m,3H),1.39(br d,J=14.1Hz,3H),1.40(br d,J=13.9Hz,3H),1.06(d,J=6.6Hz,3H),0.94(d,J=6.8Hz,3H). 19 F NMR(376MHz,DMSO-d6)δ ppm -114.27(d,J=32Hz,1F),-126.96(d,J=32Hz,1F).m / z(ESI,cation)574.1(M+H) + .
[0291] Example 19 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0292] Step 1: tert-Butyl 4-(6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate (Intermediate S). A 100 mL round-bottom flask was charged with 6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate J, 0.300 g, 0.761 mmol) and DIPEA (0.173 mL, 0.989 mmol) in acetonitrile (3.80 mL). Phosphite oxychloride (0.085 mL, 0.913 mmol) was then added slowly to the reaction mixture. The mixture was stirred and heated at 80° C. while the flask was fitted with an air-cooled condenser and placed under an inert (N2) atmosphere for 30 minutes. The reaction mixture was removed from the heat bath and allowed to cool to room temperature. The reaction mixture was cooled to 0° C. DIPEA (0.5 mL) was added slowly to the mixture. A mixture of t-butyl cis-2,6-dimethylpiperazine-1-carboxylate (0.204 g, 0.951 mmol) in MeCN (5 mL) was added slowly to the reaction mixture. The ice bath was removed and the entire mixture was allowed to warm slowly to room temperature over 10 minutes. The reaction mixture was concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-50% EtOAc / heptane) to give tert-butyl 4-(6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate as a tan solid (0.233 g, 0.395 mmol, 51.9% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 9.15(s,1H)8.55(s,1H)4.21-4.30(m,4H)3.61(br dd,J=13.58,4.46Hz,2H)2.70(quin,J=6.63Hz,2H)1.45(s,9H)1.30(d,J=6.63H z,6H)1.09(d,J=6.63Hz,6H)1.01(d,J=6.63Hz,6H).m / z(ESI, cation):590.1(M+H)+ .
[0293] Step 2: tert-Butyl 4-(6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate. To a 100 mL round bottom flask was added tert-butyl 4-(6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate (Intermediate S, 0.225 g, 0.381 mmol) and KOAc (0.112 g, 1.143 mmol) in 1,4-dioxane (2.54 mL) and the reaction mixture was degassed by bubbling N2 through the mixture for 5 min. (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.028 g, 0.038 mmol) followed by 2-fluorophenylboronic acid (0.064 g, 0.457 mmol) and water (0.1 mL) were added to the reaction mixture. The mixture was stirred and heated at 80° C. for 45 min. The reaction mixture was diluted with saturated aqueous ammonium chloride and EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-100% EtOAc / heptane) to give tert-butyl 4-(6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate as a pale yellow solid (0.219 g, 0.337 mmol, 88% yield). m / z (ESI, cation): 650.2 (M+H). + .
[0294] Step 3: 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. To a 100 mL round bottom flask was added tert-butyl 4-(6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate (0.219 g, 0.337 mmol) in DCM (3.37 mL) and trifluoroacetic acid (0.251 mL, 3.37 mmol). The reaction mixture was stirred and heated at 38° C. for 2.5 hours under an inert (N2) atmosphere. The reaction mixture was concentrated in vacuo to give crude 6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-(cis-3,5-dimethylpiperazin-1-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. This material was taken directly into the next step of the synthesis without further purification.
[0295] The crude 6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-(cis-3,5-dimethylpiperazin-1-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one was diluted with dichloromethane (3.37 mL) and the reaction mixture was then cooled to 0° C. DIPEA (0.706 mL, 4.04 mmol) was added to the reaction mixture and the mixture was stirred for 2 min. Acryloyl chloride (0.027 mL, 0.337 mmol) was added dropwise to the reaction mixture and the mixture was stirred for 30 min. The mixture was diluted with DCM and saturated aqueous NaHCO3 and the layers were then separated. The aqueous layer was extracted with DCM. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-5% MeOH / DCM) to give 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a pale yellow solid (0.080 g, 0.132 mmol, 39.3% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 8.99(s,1H)8.50(s,1H)7.42-7.48(m,1H)7.19-7.27(m,2H)7.11(t,J=7.07Hz,1H)6.74(dd, J=16.59,10.57Hz,1H)6.13(dd,J=16.59,2.28Hz,1H)5.68(dd,J=10.37,2.28Hz,1H)4.52(br s,2H)4.27(br d,J=13.68Hz,2H)3.62(dd,J=13.68,4.56Hz,2H)2.61-2.72(m,2H)1.34(br d, J = 6.63 Hz, 6H) 1.02 (d, J = 6.84 Hz, 6H) 0.86 (d, J = 6.63 Hz, 6H). m / z (ESI, positive ion): 604.0 (M + H) + .
[0296] Example 20 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0297] Step 1: 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate T). A vial was charged with tert-butyl 4-(6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate (Intermediate S, 0.76 g, 1.28 mmol), DCM (6.4 mL) and trifluoroacetic acid (1.91 mL, 25.6 mmol). The mixture was stirred at room temperature for 1 h, partitioned between EtOAc / NaHCO3, washed with NaHCO3, washed with brine, dried over MgSO4 and concentrated in vacuo to give 6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-(cis-3,5-dimethylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a crude residue.
[0298] The residue of 6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-(cis-3,5-dimethylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was redissolved in dichloromethane (6.4 mL) and then acryloyl chloride (1.74 mL, 1.92 mmol) was added dropwise. The reaction was stirred at room temperature for 30 min, partitioned between EtOAc and NaHCO3, washed with NaHCO3, washed with brine, dried over MgSO4, and purified by silica gel chromatography (eluent: 30-100% EtOAc-EtOH (3:1) / heptane) to give (4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a white solid (0.51 g, 73% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 9.16(s,1H),8.58(s,1H),6.79(dd,J=10.6,16.6Hz,1H),6.19(dd,J=2.4,16.7Hz,1H),5.74(dd,J=2.8,10.1Hz,1H),4.55(br s,2H),4.30(br d,J=13.3Hz,2H),3.69(dd,J=4.9,13.6Hz,2H),2.75-2.68(m,2H),1.35(d,J=6.8 Hz,6H),1.09(d,J=6.6Hz,6H),1.01(d,J=6.6Hz,6H).m / z(ESI,cation)544.0(M+H) + .
[0299] Step 2: 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate T, 0.26 g, 0.47 mmol), potassium trifluoro(2-fluoro-6-hydroxyphenyl)borate (0.12 g, 0.56 mmol, Intermediate L), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.03 g, 0.05 mmol) and KOAc (0.23 g, 2.34 mmol). The flask was evacuated and backfilled with N2, after which 1,4-dioxane (1.8 mL) and water (0.47 mL) were added. The mixture was stirred at 90 °C for 18 h and purified by silica gel chromatography (eluent: 30-60% EtOAc-EtOH (3:1) / heptane) to give 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a yellow solid (0.13 g, 44.8% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 10.13(br s,1H),9.04(s,1H),8.54(s,1H),7.27-7.19(m,1H),6.81(dd,J=10.6,16.6Hz,1 H),6.73-6.63(m,2H),6.20(dd,J=2.4,16.7Hz,1H),5.78-5.72(m,1H),4.58(br s,2H),4.34(br d,J=13.7Hz,2H),3.66(dd,J=4.6,13.7Hz,2H),2.75-2.68(m,2H),1.42(br d,J=6.6Hz,6H),1.08(d,J=6.6Hz,6H),0.97-0.90(m,6H). 19F NMR(376MHz,DMSO-d6)δ ppm -116.05(s,1F).m / z(ESI,cation)620.0(M+H) + .
[0300] Example 21 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0301] 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate T, 0.26 g, 0.47 mmol), potassium carbonate (0.14 g, 2.31 mmol), (2-amino-6-fluorophenyl)boronic acid pinacol ester (0.12 g, 0.52 mmol, Enamine, San Diego, Calif.), tetrakis(triphenylphosphine)palladium(0) (54 mg, 0.05 mmol) and 1,4-dioxane (1.6 mL). The mixture was degassed with N2, water (0.7 mL) was added, and the mixture was stirred at 90 °C for 2 h, then cooled to room temperature, adsorbed directly onto SiO2, and purified by silica gel chromatography (eluent: 30-60% EtOAc-EtOH (3:1) / heptane) to give 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(4,6-diisopropylpyrimidin-5-yl)pyrido[2,3-d]pyrimidin-2(1H)-one as a yellow solid (0.045 g, 0.073 mmol, 15.5% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 9.05(s,1H),8.53(s,1H),7.11-6.97(m,1H),6.82(dd,J=10.5,16.7Hz,1H),6.44(d,J=8. 4Hz,1H),6.31(t,J=9.0Hz,1H),6.20(dd,J=2.4,16.7Hz,1H),5.78-5.73(m,1H),5.09(br s,2H),4.60(br s,2H),4.32(br d,J=13.3Hz,2H),3.68(ddd,J=4.8,8.8,13.6Hz,2H),2.92-2.81(m,1H),2.66-2.61(m,1H),1.47-1.35(m,6H),1.12-0.93(m,12H). 19F NMR(376MHz,DMSO-d6)δ ppm -116.31(s,1F).m / z(ESI, cation)619.6(M+H) + .
[0302] Example 22 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0303] Step 1: 1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione. A 100 mL round bottom flask was charged with 7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate N, 0.420 g, 1.11 mmol) and KOAc (0.327 mL, 3.34 mmol) in 1,4-dioxane (5.56 mL). The reaction mixture was degassed by bubbling (N2) gas through the mixture for 5 minutes. Then, (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (0.081 g, 0.111 mmol) was added to the reaction mixture. The mixture was stirred and heated at 95° C. for 10 min. 2-Fluorophenylboronic acid (0.187 g, 1.33 mmol) and water (0.1 mL) were added to the reaction mixture. The entire mixture was stirred at 95° C. for 16 h. The reaction mixture was diluted with saturated aqueous ammonium chloride and EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-100% EtOAc / heptane) to give 1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (0.235 g, 0.537 mmol, 48.3% yield) as a pale yellow solid. 1 H NMR(400MHz,DMSO-d6)δ ppm 12.27(br s,1H)9.12(s,1H)8.46(d,J=8.50Hz,1H)7.48-7.57(m,1H)7.20-7.36(m,3H)2.88-3. 08(m,2H)1.10(d,J=6.63Hz,6H)0.94(d,J=6.63Hz,6H).m / z(ESI, cation):438.1(M+H) + .
[0304] Step 2: tert-Butyl 4-(1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate. A 100 mL round-bottom flask was charged with 1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (0.105 g, 0.240 mmol) and DIPEA (0.054 mL, 0.312 mmol) in acetonitrile (1.20 mL). Phosphorous acid oxychloride (0.027 mL, 0.288 mmol) was then added slowly to the reaction mixture. The mixture was stirred and heated at 80° C. while the flask was fitted with an air-cooled condenser and then placed under an inert (N2) atmosphere for 30 minutes. The reaction mixture was removed from the heat bath and allowed to cool to room temperature. The reaction mixture was cooled to 0° C. Then DIPEA (0.5 mL) was slowly added to the mixture. Then a mixture of (2R,6S)-tert-butyl 2,6-dimethylpiperazine-1-carboxylate (0.064 mL, 0.300 mmol) in acetonitrile (1 mL) was slowly added to the reaction mixture. The ice bath was removed and the entire mixture was allowed to warm slowly to room temperature over 10 minutes. The reaction mixture was concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by chromatography (eluent: 0-70% EtOAc / heptane) to give tert-butyl 4-(1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate as a pale yellow solid (0.105 g, 0.166 mmol, 69.0% yield). m / z (ESI, positive ion): 634.3 (M+H). + .
[0305] Step 3: 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. To a 100 mL round bottom flask was added tert-butyl 4-(1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate (0.100 g, 0.158 mmol) in DCM (1.97 mL) and trifluoroacetic acid (0.118 mL, 1.58 mmol). The reaction mixture was stirred and heated at 38° C. under an inert (N2) atmosphere for 2.5 h. The reaction mixture was concentrated in vacuo to give 1-(4,6-diisopropylpyrimidin-5-yl)-4-(cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a crude residue. This material was taken directly into the next step of the synthesis without further purification.
[0306] The residue of 1-(4,6-diisopropylpyrimidin-5-yl)-4-(cis-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one was diluted with dichloromethane (1.97 mL) and the reaction mixture was cooled to 0° C. Then, DIPEA (0.331 mL, 1.89 mmol) was added to the reaction mixture, which was stirred for 2 min. Acryloyl chloride (0.013 mL, 0.158 mmol) was added dropwise to the reaction mixture. The reaction mixture was stirred for 30 min. The mixture was diluted with DCM and saturated aqueous NaHCO3, then the layers were separated. The aqueous layer was extracted with DCM. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was adsorbed onto a plug of silica gel and purified by silica gel chromatography (eluent: 0-4% MeOH / DCM) to give 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluorophenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a pale yellow solid (0.080 g, 0.136 mmol, 86% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 9.10(s,1H)8.43(d,J=9.74Hz,1H)7.56(q,J=7.05Hz,1H)7.23-7.38(m,3H)6.81(d d,J=16.48,10.47Hz,1H)6.20(dd,J=16.69,1.97Hz,1H)5.73-5.79(m,1H)4.57(br s,2H)4.30-4.40(m,2H)3.73(dd,J=13.58,4.66Hz,2H)2.54-2.79(m,2H)1.41(br d, J = 6.63 Hz, 6H) 1.10 (d, J = 6.63 Hz, 6H) 0.94 (d, J = 6.63 Hz, 6H). m / z (ESI, positive ion): 588.2 (M + H) + .
[0307] Example 23 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0308] Step 1: tert-Butyl 4-(7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate. Phosphorous acid oxychloride (0.34 mL, 3.63 mmol) was added dropwise to a solution of 7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (Intermediate N, 0.5 g, 1.32 mmol) and DIPEA (0.69 mL, 3.93 mmol) in acetonitrile (1.3 mL). The mixture was heated to 80° C. for 1 h and then cooled to 0° C. DIPEA (1.58 mL, 9.07 mmol) and t-butyl cis-2,6-dimethylpiperazine-1-carboxylate (0.30 g, 1.39 mmol, Enamine, San Diego, Calif.) were added. The mixture was allowed to warm to room temperature and stirred for 1 h, then poured into a cold solution of saturated NaHCO3 and stirred vigorously for 10 min. The mixture was partitioned between EtOAc and brine, the layers were separated, the aqueous layer was back-extracted with EtOAc, and the combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography (eluent: 0-40% EtOAc-EtOH (3:1) / heptane) to give tert-butyl 4-(7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate as a white solid (0.59 g, 78% yield), which was used without further purification. m / z (ESI, positive ion) 574.0 (M+H). +.
[0309] Step 2: 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate U). A vial was charged with tert-butyl 4-(7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-2-oxo-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-cis-2,6-dimethylpiperazine-1-carboxylate (0.59 g, 1.03 mmol), DCM (5.2 mL) and trifluoroacetic acid (1.53 mL, 20.5 mmol). The mixture was stirred at room temperature for 1 h and partitioned between EtOAc and NaHCO3. The organic layer was washed with NaHCO3, washed with brine, dried over MgSO4 and concentrated in vacuo to give 7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-(cis-3,5-dimethylpiperazin-1-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one as a crude residue.
[0310] The residue of 7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-4-(cis-3,5-dimethylpiperazin-1-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one was redissolved in dichloromethane (5.2 mL) and acryloyl chloride (2.42 mL, 2.66 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 30 min and partitioned between EtOAc and NaHCO3. The organic layer was washed with NaHCO3, washed with brine, dried over MgSO4, and purified by silica gel chromatography (eluent: 30-100% EtOAc-EtOH (3:1) / heptane) to give 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one as a white solid (0.44 g, 82% yield). 11H NMR (400 MHz, DMSO-d6) δ ppm 9.16 (s, 1H), 8.46 (d, J = 8.5 Hz, 1H), 6.79 (dd, J = 10.6, 16.6 Hz, 1H), 6.18 (dd, J = 2.4, 16.7 Hz, 1H), 5.78 - 5.72 (m, 1H), 4.54 (br s, 2H), 4.30 (dd, J = 2.5, 13.7 Hz, 2H), 3.71 (dd, J = 4.8, 13.7 Hz, 2H), 2.73 - 2.65 (m, 2H), 1.34 (d, J = 6.6 Hz, 6H), 1.09 (d, J = 6.6 Hz, 6H), 1.00 (d, J = 6.6 Hz, 6H). 19 19F NMR (376 MHz, DMSO-d6) δ ppm -127.69 (s, 1F). m / z (ESI, positive ion) 528.0 (M + H) + .
[0311] Step 3: 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate U, 0.22 g, 0.42 mmol), potassium trifluoro(2-fluoro-6-hydroxyphenyl)borate (0.11 g, 0.51 mmol, Intermediate L), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.03 g, 0.04 mmol) and KOAc (0.21 g, 2.10 mmol). The flask was evacuated and backfilled with N2, after which 1,4-dioxane (1.7 mL) and water (0.4 mL) were added. The mixture was stirred at 90 °C for 2 h, then cooled to room temperature and purified by silica gel chromatography (eluent: 30-60% EtOAc-EtOH (3:1) / heptane) to give 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one as a yellow solid (0.13 g, 49% yield). 1 H NMR(400MHz,DMSO-d6)δ ppm 10.21(br s,1H),9.05(s,1H),8.36(d,J=9.3Hz,1H),7.30-7.23(m,1H),6.84-6.65(m,3H),6.19(dd,J=2.4,16.7Hz,1H),5.78-5.72(m,1H),4.56(br s,2H),4.33(dd,J=2.4,13.6Hz,2H),3.69(dd,J=4.7,13.6Hz,2H),2.74-2.6 4(m,2H),1.41(d,J=6.8Hz,6H),1.08(d,J=6.6Hz,6H),0.93(d,J=6.6Hz,6H). 19F NMR(376MHz,DMSO-d6)δ ppm -115.89(s,1F),-128.23(s,1F).m / z(ESI, cation)604.1(M+H) + .
[0312] Example 24 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one [ka]
[0313] 4-(4-Acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one. A vial was charged with 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-chloro-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one (Intermediate U, 0.22 g, 0.42 mmol), potassium carbonate (0.29 g, 2.10 mmol), (2-amino-6-fluorophenyl)boronic acid pinacol ester (0.11 g, 0.46 mmol, CombiPhos, Trenton, NJ), tetrakis(triphenylphosphine)palladium(0) (49 mg, 0.042 mmol), water (0.7 mL) and 1,4-dioxane (1.4 mL). The mixture was degassed with nitrogen and stirred at 90 °C for 2 h, then cooled to room temperature and purified by silica gel chromatography (eluent: 30-60% EtOAc-EtOH (3:1) / heptane) to give 4-(4-acryloyl-cis-3,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-diisopropylpyrimidin-5-yl)-6-fluoropyrido[2,3-d]pyrimidin-2(1H)-one as a yellow solid (0.10 g, 40% yield).1 1H NMR (400 MHz, DMSO-d6) δ ppm 9.09 (s, 1H), 8.37 (d, J = 9.5 Hz, 1H), 7.13 - 7.06 (m, 1H), 6.81 (dd, J = 10.6, 16.8 Hz, 1H), 6.47 (d, J = 8.3 Hz, 1H), 6.36 (t, J = 9.1 Hz, 1H), 6.20 (dd, J = 2.5, 16.6 Hz, 1H), 5.78 - 5.73 (m, 1H), 5.29 (s, 2H), 4.58 (m, 2H), 4.34 - 4.30 (m, 2H), 3.71 (dd, J = 4.8, 13.7 Hz, 2H), 2.78 - 2.68 (m, 2H), 1.41 (d, J = 6.6 Hz, 6H), 1.08 (d, J = 6.6 Hz, 6H), 0.94 (d, J = 6.6 Hz, 6H). 19 19F NMR (376 MHz, DMSO-d6) δ ppm -115.21 (d, J = 22.5 Hz, 1F), -127.18 (d, J = 22.5 Hz, 1F). m / z (ESI, positive ion) 603.6 (M + H) + .
[0314] Table 2: Biochemical Activity and Cellular Activity of Compounds The following assay conditions were utilized for the compounds in Table 2: Nucleotide pair exchange assay: Purified GDP-bound KRAS protein (aa 1-169) containing both G12C and C118A amino acid substitutions and an N-terminal His tag was pre-incubated for 5 minutes in assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2 and 0.01% Triton X-100) with compound dose-response titration. Following compound pre-incubation, purified SOS protein (aa 564-1049) and GTP (Roche 10106399001) were added to the assay wells and incubated for an additional 30 minutes. To determine the extent of inhibition of SOS-mediated nucleotide exchange, purified GST-tagged cRAF (aa 1-149), nickel-chelating AlphaLISA acceptor beads (PerkinElmer AL108R) and AlphaScreen glutathione donor beads (PerkinElmer 6765302) were added to the assay wells and incubated for 5 min. The assay plates were then read on a PerkinElmer EnVision Multilabel Reader using AlphaScreen® technology and the data were analyzed using a four-parameter logistic model to determine the IC 50 values were calculated.
[0315] Phospho-ERK1 / 2 MSD Assay: MIA PaCa-2 (ATCC® CRL-1420™) and A549 (ATCC® CCL-185™) cells were cultured in RPMI 1640 medium (ThermoFisher Scientific 11875093) containing 10% fetal bovine serum (ThermoFisher Scientific 16000044) and 1× Penicillin-Streptomycin-Glutamine (ThermoFisher Scientific 10378016). MIA PaCa-2 or A549 cells were seeded into 96-well cell culture plates at a density of 25,000 cells / well 16 hours prior to compound treatment and incubated at 37° C., 5% CO2. Compound dose-response titrations were diluted in growth medium and added to the appropriate wells of the cell culture plate followed by incubation at 37° C., 5% CO2 for 2 hours. After compound treatment, cells were stimulated with 10 ng / mL EGF (Roche 11376454001) for 10 min and then incubated with ice-cold Dulbecco's phosphate-buffered saline (Ca 2+ or Mg 2+ Cells were washed with 100 mM Tris-HCl pH 7.5 (ThermoFisher Scientific 14190144) and subsequently lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 1% Igepal, 0.5% sodium deoxycholate, 150 mM NaCl and 0.5% sodium dodecyl sulfate) containing protease inhibitors (Roche 4693132001) and phosphatase inhibitors (Roche 4906837001). Phosphorylation of ERK1 / 2 in compound-treated lysates was assayed using the Phospho-ERK1 / 2 Whole Cell Lysate kit (Meso Scale Discovery K151DWD) according to the manufacturer's instructions. Assay plates were read on a Meso Scale Discovery Sector Imager 6000 and data were analyzed using a four-parameter logistic model to determine IC 50 values were calculated.
[0316] In Table 2 below, "--" means that the assay was not performed.
[0317] [Table 8]
[0318] [Table 9]
[0319] The present invention has been described in connection with preferred embodiments. However, it should be understood that the present invention is not limited to the disclosed embodiments. Given the description of the embodiments of the present invention herein, it is understood that various modifications may be made by those skilled in the art. Such modifications are encompassed within the scope of the following claims.
Claims
1. Formula (I) 【Chemistry 1】 (In the formula, A is independently N or CH; W is independently N or CH; One or both of A and W is N; R 1 and R 2 are independently halo, -C 1 ~C 8 Alkyl, -C 2 ~C 8 Alkenyl, -C 2 ~C 8 Alkynyl, -OCF 3 , -NO 2 , -CN, -NC, -OH, alkoxy, amino, -CO 2 H, -CO 2 C 1 ~C 8 Alkyl, -OCOC 1 ~C 8 Alkyl, -C 3 ~C 10 Cycloalkyl, -C 3 ~C 10 Heterocycloar, -C 5 ~C 10 Aryl or -C 5 ~C 10 is heteroaryl; R 3 is one or two R 5 is a phenyl substituted by a substituent; R 5 independently represents one or more of halo, —OH or NH 2 Selected from: R 4 is a halo) or a stereoisomer thereof, an atropisomer thereof, a pharma- ceutically acceptable salt thereof, a pharma- ceutically acceptable salt of said stereoisomer, or a pharma- ceutically acceptable salt of said atropisomer.
2. Formula (Ia) 【Chemistry 2】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
3. 3. The compound or salt of claim 1 or 2, wherein A is N.
4. 3. The compound or salt of claim 1 or 2, wherein W is N.
5. 3. The compound or salt of claim 1 or 2, wherein A is N and W is N.
6. R 1 and R 2 are independently -C 1 ~C 8 Alkyl or -C 3 ~C 10 The compound or salt according to any one of claims 1 to 5, which is cycloalkyl.
7. R 1 and R 2 The compound or salt of claim 6, wherein is independently isopropyl or cyclopropyl.
8. R 3 teeth, 【Chemistry 3】 The compound or salt according to any one of claims 1 to 7,
9. R 3 teeth, 【Chemistry 4】 9. The compound or salt of claim 8,
10. R 4 The compound or salt according to any one of claims 1 to 9, wherein is Cl.
11. R 4 The compound or salt according to any one of claims 1 to 9, wherein is F.
12. 【Fig. 5】 3. The compound of claim 2, wherein:
13. 【Chemical Formula 6】 3. The compound of claim 2, wherein:
14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 and a pharma- ceutically acceptable excipient.
15. 15. The pharmaceutical composition of claim 14 for use in treating cancer.
16. The pharmaceutical composition of claim 14, wherein the cancer is non-small cell lung cancer, small intestine cancer, appendix cancer, colorectal cancer, endometrial cancer, pancreatic cancer, skin cancer, gastric cancer, nasal cancer or bile duct cancer.
17. The pharmaceutical composition of claim 16, wherein the cancer is non-small cell lung cancer.
18. The pharmaceutical composition of claim 16, wherein the cancer is colorectal cancer.
19. The pharmaceutical composition of claim 16, wherein the cancer is pancreatic cancer.
20. The pharmaceutical composition according to any one of claims 15 to 19, wherein the cancer has a KRAS G12C mutation.
21. Use of a compound according to any one of claims 1 to 12 for the manufacture of a medicament for the treatment of cancer.
22. 22. The use according to claim 21, wherein the cancer is non-small cell lung cancer, small intestine cancer, appendix cancer, colorectal cancer, endometrial cancer, pancreatic cancer, skin cancer, gastric cancer, nasal cancer or bile duct cancer.
23. 23. The use of claim 22, wherein the cancer is non-small cell lung cancer.
24. 23. The use according to claim 22, wherein the cancer is colorectal cancer.
25. 23. The use of claim 22, wherein the cancer is pancreatic cancer.
26. The use according to any one of claims 21 to 25, wherein the cancer has a KRAS G12C mutation.
27. 1. A pharmaceutical composition for use in treating cancer harboring a KRAS G12C mutation, comprising a compound and a pharma- ceutical acceptable excipient, said compound comprising: 【Chemistry 7】 or a pharma- ceutical acceptable salt thereof, and the cancer is non-small cell lung cancer, colorectal cancer, or pancreatic cancer.
28. 28. The pharmaceutical composition of claim 27, wherein the cancer is non-small cell lung cancer.
29. 28. The pharmaceutical composition of claim 27, wherein the cancer is colorectal cancer.
30. 28. The pharmaceutical composition of claim 27, wherein the cancer is pancreatic cancer.
31. 1. A pharmaceutical composition for use in treating cancer harboring a KRAS G12C mutation, comprising a compound and a pharma- ceutical acceptable excipient, said compound comprising: 【Chemistry 8】 and the cancer is non-small cell lung cancer, colorectal cancer, or pancreatic cancer.
32. 32. The pharmaceutical composition of claim 31 , wherein the cancer is non-small cell lung cancer.
33. 32. The pharmaceutical composition of claim 31 , wherein the cancer is colorectal cancer.
34. 32. The pharmaceutical composition of claim 31 , wherein the cancer is pancreatic cancer.
35. Use of a compound for the manufacture of a medicament for the treatment of a cancer having a KRAS G12C mutation, said compound comprising: 【Chemistry 9】 or a pharma- ceutically acceptable salt thereof, and the cancer is non-small cell lung cancer, colorectal cancer, or pancreatic cancer.
36. 36. The use of claim 35, wherein the cancer is non-small cell lung cancer.
37. 36. The use of claim 35, wherein the cancer is colorectal cancer.
38. 36. The use of claim 35, wherein the cancer is pancreatic cancer.
39. Use of a compound for the manufacture of a medicament for the treatment of a cancer having a KRAS G12C mutation, said compound comprising: 【Chemistry 10】 and the cancer is non-small cell lung cancer, colorectal cancer, or pancreatic cancer.
40. 40. The use of claim 39, wherein the cancer is non-small cell lung cancer.
41. 40. The use of claim 39, wherein the cancer is colorectal cancer.
42. 40. The use of claim 39, wherein the cancer is pancreatic cancer.
Citation Information
Patent Citations
Inhibitor of krasg12c
JP2016532656A
1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[3-oxo-4h-pyrido[2] as raf inhibitors for the treatment of cancer ,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives
JP2016538345A
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as KRAS G12C inhibitors for the treatment of lung, pancreatic or colorectal cancer
JP2020504738A
Fused-tricyclic inhibitors of KRAS and methods of use thereof
WO2016168540A1
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017087528A1
